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Abstract 
Despite the wealth of literature supporting a harm reduction approach to substance use, it 
remains challenging to implement evidence into policy. As Canada expands its harm reduction 
services, it is important to address that controversial community perceptions of harm reduction 
and substance use negatively impact the goals of this work.  
This project is based on a literature review on community perceptions of harm reduction and 
people who use drugs. Health professionals and clients have identified stigma in health care, and 
in broader society, as a barrier to optimal service provision. The project addresses this problem 
with a set of guidelines for health professionals on destigmatizing harm reduction work. The 
guidelines clarify misperceptions about harm reduction, outline the harmful impact of stigma on 
health outcomes, and promote actions associated with reduced stigma and enhanced health 
outcomes. Such actions include self-care, reflection on ethics, and supporting the dignity and 
autonomy of clients. 
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Part One: Introduction 
The opioid crisis in Canada has brought urgency to reevaluating our country’s response 
to drug use. The traditional model of drug control, enforcement and criminalization, has failed to 
deter drug use (UK Home Office, 2014; Zábransk!, 2004) and has had the perverse effect of 
increasing harms associated with drug use (Beletsky et al., 2014; Global Commission on HIV 
and the Law, 2012; Kerr, Small & Wood, 2005; Werb et al., 2011). Thousands of preventable 
deaths indicate that efforts to reduce the harms associated with drug use are lacking. Experts in 
health and policy, such as the World Health Organization, the United Nations Office on Drugs 
and Crime, the Joint United Nations Program on HIV/AIDS, the Global Commission on Drug 
Policy, and the Global Commission on HIV and the Law, are calling for a shift from a criminal 
model of drug policy to a harm reduction model (Global Commission on Drug Policy, 2016; 
Global Commission on HIV and the Law, 2012; WHO, UN Office on Drugs and Crime & UN 
Joint Programme on HIV/AIDS, 2012).  Harm reduction services like needle and syringe 
programs (NSP), opioid agonist treatment (OAT) and safe injection facilities (SIF) have been 
effective in decreasing injection drug related rates of human immunodeficiency virus  (HIV) and 
hepatitis C virus (HCV) (Fernandes et al., 2017; MacArthur et al., 2012; MacArthur et al., 2014; 
Palmateer, 2014; Turner et al., 2011). Such services have also decreased risk behaviours 
associated with injection drug use such as syringe sharing, syringe reuse, and injecting in public 
spaces (MacArthur et al., 2014; Potier, Laprévote, Dubois-Arber, Cottencin & Rolland, 2014). 
Furthermore, harm reduction decreases rates of overdose, increases access to treatment, and has 
shown economic benefits with savings in health care and social justice systems (Hughes & 
Stevens, 2010; McCollister & French, 2003; Potier et al., 2014; Wilson, Donald, Shattock, 
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Wilson & Fraser-Hurt, 2015; WHO, UN Office on Drugs and Crime & UN Joint Programme on 
HIV/AIDS, 2004). 
 Despite the substantial evidence base that supports harm reduction, researchers and health 
professionals have expressed concern around the lack of implementation of evidence into drug 
policy and health care practice (Eggertson, 2013; Reuter, 2001). Research identifies political 
agendas, and stigmatizing attitudes towards drug use and people who use drugs (PWUD) as key 
barriers to the much-needed expansion of harm reduction practices (Canadian Nurses 
Association, 2012; Coomber, 2010; Kerr, Mitra, Kennedy & McNeil, 2017; Singleton & Rubin, 
2014). Health professionals report that negative community attitudes towards PWUD, even 
among their colleagues, impede optimal provision of harm reduction services in their 
communities (Hobden & Cunningham, 2006; Pauly, 2008a; Shepard, 2013). Discrimination 
towards PWUD is reported as a barrier for accessing treatment, and for practicing safer drug use 
strategies (Boucher et al., 2017; Bozinoff, 2017).  Stigma and discrimination reported within 
harm reduction and health care services is especially concerning as it violates the human right of 
equal access to health care services (Pauly, 2008a; Van Boekel, Brouwers, Van Weeghel & 
Garretsen, 2013). If negative perceptions of PWUD are limiting the benefits of harm reduction, 
this is a problem that needs to be addressed in order to optimize health service outcomes and 
effectively respond to the opioid crisis. 
Significance of the Project 
Research suggests that further training or education opportunities can better equip health 
professionals for ethical challenges they face in their work, such as systemic discrimination of 
PWUD (Van Boekel et al., 2013).  Although useful instructions on upholding the principles of 
harm reduction in health care settings are available (Hawk et al., 2017), they do not address how 
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the values of harm reduction are undermined by normalized societal stigma towards PWUD. 
This means well-intentioned health professionals may accept the guiding philosophy of harm 
reduction without examining or understanding the ways in which systemic stigma and personal 
biases conflict with the ethics of their work, and negatively impact client care and health 
outcomes. 
This project is a guidebook for addressing and decreasing stigma in harm reduction work. 
It includes a set of guidelines based on research findings on stigma and discrimination towards 
PWUD. The intention is to raise awareness about the ways that societal stigma impacts health 
and wellness outcomes for PWUD.  The guide is written for people who work in the field of 
substance use and addiction under a harm reduction framework. The guidelines confront 
stigmatizing beliefs, and address misperceptions about harm reduction and PWUD in order to 
facilitate anti-oppressive health service environments. Organizations or individuals may use it as 
an education, training, or professional development tool.  The guidelines include the perspectives 
of PWUD, researchers, and health professionals. The over-arching goal of the project is to 
decrease stigma in health care and in society at large to better support evidence-based drug 
policy and wellness outcomes for PWUD. 
Background of the Project 
 Graduate studies brought me to Northern B.C., where I became interested in 
understanding how harm reduction practices are received by northern communities, especially in 
contrast to larger urban cities, such as Vancouver, where I completed my undergraduate studies. 
When I finished my literature review on the topic of community perceptions of harm reduction 
and PWUD, I found that there was a rich amount of information on the topic of addressing the 
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stigma and misperceptions that surround harm reduction, and I decided to make this the project 
focus. 
 The project began to take shape after completing my workplace orientation that gave new 
staff members a basic overview of the values and principles of harm reduction within our 
organization. These guiding principles such as being respectful, non-judgmental and maximizing 
client options are integral to harm reduction work. However, they do not go as far as directly 
challenging commonly held stigmatizing perceptions towards harm reduction and PWUD that 
are pervasive in society and health care settings. It is important that professionals in substance 
use work are prepared for addressing this ethical issue. 
Researcher Positioning  
During my undergraduate studies, my involvement in the Canadian Students for Sensible 
Drug Policy alerted me to the lack of research involved in drug policy. It is unacceptable that in 
the context of drug control, peoples’ prejudice about illicit drug use and PWUD impacts policy 
more than research and evidence. Currently, my work in mental health motivates me to combat 
stigma, and promote understanding around mental health issues. From a feminist counselling 
theory approach, understanding people and their motivations requires an examination of their 
surrounding social systems. We cannot condemn an individual for their addiction without being 
critical of the social systems that support, and may perpetuate, their behaviour. Feminist theory 
defines the goals of counselling as creating change for individuals that supports their personal 
goals, and changing society through challenging the constraints of socialized roles, 
discrimination and oppression (Corey, 2013).  This proposed project is an opportunity for me to 
live the values of my practice, and advocate for basic human rights of human dignity and health 
care for PWUD.  
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Clarification of Terms 
 Drug use and people who use drugs. Many people use drugs for reasons that are social, 
health-related, performance enhancing, and for coping with the pains and struggles of life. Many 
drugs that have high potential for addiction or misuse require a prescription, with obvious 
exceptions such as caffeine, alcohol, and nicotine, while others have been deemed illicit 
substances, thereby criminalizing those who use them. The term ‘people who use drugs’ includes 
most people in society, but for the purposes of this paper, it will be used to refer to people who 
use illicit drugs. In the same way, the term ‘drug use’ will mainly refer to use of illicit drugs. 
 Harm reduction. The practice of harm reduction is another common part of many 
peoples’ lives. Use of seatbelts, helmets, condoms, and sunscreen, are practices that reduce risk 
of harm. Community harm reduction services are typically aimed at reducing risk of harms from 
legal and illegal sexual activity, and substance use. Since this proposed research is focused on 
harm reduction pertaining to substance use, the term will be used to refer to substance use harm 
reduction. 
Overview of the Project 
 As Canada is expanding its harm reduction services and responding to the opioid crisis, 
the stigma and misperceptions about harm reduction that create barriers to evidence-based drug 
policy are problematic. This project addresses harmful and misinformed views of harm reduction 
and PWUD. It will summarize recommendations from research on this topic into a guidebook for 
decreasing the stigma around harm reduction work. The guide will be written for people who 
work in the field of harm reduction and substance use services.  
 What follows in part two will be a literature review on harm reduction that begins with an 
overview of the research on harm reduction service outcomes, which will be contrasted with law 
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enforcement drug control, to highlight the importance of rethinking the way society responds to 
drug use. Next, it will summarize the challenges involved in raising awareness of the benefits 
harm reduction, and implementing evidence-based drug policy. It will then provide an overview 
of the research on community perceptions of harm reduction, drug use and PWUD. The literature 
review will end with examining the implications of stigma on health outcomes among PWUD, 
and recommendations for addressing stigma in health services settings. 
 Part three will outline the proposed project plan. It will outline the project format, the 
target audience, and the step-by-step process of summarizing the research into guidelines. 
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Part Two: Literature Review 
 The history of stigma associated with illicit drug use and PWUD continues to negatively 
impact the quality and availability of evidence-based harm reduction services (Kulesza, 
Teachman, Werntz, Gasser, & Lindgren, 2015; Pauly, 2008a; Van Boekel et al., 2013; Wild, et 
al., 2017). The benefits of harm reduction are well documented (Fernandes et al., 2017; 
MacArthur et al., 2014; Potier et al., 2014). Harm reduction has been endorsed as best practice 
response to problems associated with substance use by prominent international organizations 
(WHO et al., 2012).  In order to optimize harm reduction strategies, especially in response to the 
current fentanyl crisis, it is important to review how stigma and misperceptions about harm 
reduction, drug control, and substance use, are impacting service provision.  Part two will 
provide a review of the research on harm reduction services for substance use. It will begin with 
an examination of both criminalization and harm reduction as responses to problematic substance 
use. Next, it will outline why evidence-based drug policy has been met with resistance from 
governments and communities. It will then examine the role of public perceptions in the 
provision and expansion of harm reduction services. The final part of this section will outline 
recommendations for decreasing stigma, and increasing positive attitudes towards harm 
reduction and PWUD in health care settings. 
Harm Reduction, Criminalization and Enforcement Drug Policy 
Harm reduction, as it pertains to substance use, can be defined as a policy, program or 
intervention with the prime directive of reducing drug related harms on PWUD and the broader 
community. Rather than targeting drug use, harm reduction targets risks associated with drug 
use. This means that decreasing or eliminating drug use is not a requirement of successful harm 
reduction, however, these actions may be considered a form of harm reduction in cases where 
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they are part of individuals’ goals for reducing risk and promoting health (Lenton & Single, 
1998).  Harm reduction can be misunderstood as condoning drug use, and thereby opposing the 
prohibition of drugs. However, the philosophy of harm reduction is neutral on moral and legal 
assessments of drug policy, and instead assesses the impact that policy has on health, social, and 
economic problems, associated with drug use (Erickson, 1995; Harm Reduction International).  
Harm reduction and law enforcement drug control, to some extent, share the same goal of 
reducing the harmful consequences of drug use. Striking differences between enforcement and 
harm reduction are that enforcement is not based on evidence or cost-benefit analysis (Singleton 
& Rubin, 2014), it targets drug use rather than the harms of drug use, and it includes punitive 
measures that create social and legal harms for PWUD. 
 Decreasing harms of illicit drug use. In 1998, a UN General Assembly Special Session 
on Drugs was held around the theme, “A Drug-Free World – We can do it”. This assembly 
endorsed law enforcement drug control and criminalization of illicit drug possession, production 
and trafficking (Csete et al., 2016). Almost twenty years later, the 2017 UN World Drug Report 
shows that rates of drug use and opium field production have remained stable (United Nations 
Office on Drugs and Crime, 2017). Though world-wide statistics are often too general to 
extrapolate useful information from, what is clear is that efforts to eradicate substance use have 
been futile. In 2014, the United Kingdom government reviewed specific drug policies in eleven 
countries ranging from highly punitive criminal justice models to decriminalization. There was 
no relationship found between levels of drug use and the severity of criminal justice enforcement 
(UK Home Office, 2014). Furthermore, research on the impact of incarceration on drug use 
cessation shows no change in rates of drug use before and after a period of incarceration among 
people incarcerated for drug use. The same study found incarceration to be negatively correlated 
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with drug use cessation whereas methadone treatment was positively correlated with drug use 
cessation (DeBeck et al., 2009). 
In the Czech Republic, 1998, the government commissioned a team of academic 
researchers to review the impact of their strict prohibition drug policy. Six years later, the team 
found that rates of problematic drug use, and the availability of drugs, were not impacted. They 
also noted the high cost of increased policing and incarceration. As a result of their findings, the 
Czech Republic organized a team of drug policy planners, including people with firsthand 
experience in health and social services with PWUD, to develop a more effective drug policy 
framework. This resulted in decriminalization of use and possession of illicit drugs below a 
defined amount (Zábransk!, 2004). 
 Decreasing or eradicating drug use has been shown to be futile over human history. The 
Russian Tsars in the 1600s tortured and threatened to execute people for tobacco use, but even 
these harsh measures were not able to dissuade use (Starks & Krementsov, 2017). While drug 
use seems to be a human behaviour that is here to stay, the problems and harms associated with 
drug use are changeable.  
Harm reduction practices such as needle and syringe programs (NSP), safe injection 
facilitates (SIF) and opioid agonist treatments (OAT) have been successful in decreasing 
infectious diseases such as human immunodeficiency virus (HIV), hepatitis C virus (HCV) and 
tuberculosis (TB) (Aspinall et al., 2014; Fernandes et al., 2017; Grenfell et al., 2013; MacArthur 
et al., 2014).  Meta-analyses demonstrated that OATs and NSPs reduce risk of HIV transmission 
among people who inject drugs by roughly 50% (MacArthur et al., 2012; MacArthur et al., 
2014). Harm reduction programs have also been found effective at reducing risk behaviours 
associated with injection drug use such as syringe sharing, syringe reuse, public injecting, and 
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publicly discarded needles (European Monitoring Centre for Drugs and Drug Addiction, 2016; 
MacArthur et al., 2014; Potier et al., 2014; Wood et al., 2004). In a community surrounding an 
Australian NSP, there were fewer reports of public nuisances related to drug use (Salmon, Thein, 
Kimber, Kaldor & Maher, 2007). In Vancouver, following the opening of North America’s first 
SIF, overdose deaths dropped by 35% (Marshall, Milloy, Wood, Montaner, & Kerr, 2011). A 
meta-analysis found that no deaths by overdose have ever taken place within the reviewed SIFs 
(Potier et al., 2014). 
 The benefits of harm reduction are not just reduction of negative consequences, but 
increases in positive results such as more people seeking treatment for substance dependence 
(Hughes & Stevens, 2010; Potier et al., 2014). Research on Vancouver’s SIF showed that 18% of 
people who used the facility took part in a detoxification program (Wood et al., 2006), 57% 
started addiction treatment, and 23% stopped using injection drugs (DeBeck et al., 2011). 
Additional benefits include increased opportunities for social connection, support and feelings of 
belonging, all of which contribute to better treatment outcomes and overall quality of life for 
PWUD (Boucher et al., 2017; Lago, Peter & Bógus, 2017) 
 Increased harms associated with drug use. Punitive drug policy increases the harmful 
risks associated with drug use. Risk of arrest, a criminal record, and social marginalization are 
not caused by drugs but by social rules and attitudes about drugs (Global Commission on Drug 
Policy, 2016). Criminalization and enforcement drug control have been found to exacerbate 
problems and harms associated with drug use and the illicit drug market. Systematic reviews on 
the impact of enforcement on drug markets show that increased enforcement is associated with 
increased violence and volatility among PWUD and drug dealers, and increased homicide rates 
in the drug market (Kerr, Small & Wood, 2005; Werb et al., 2011). Increased enforcement 
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intensifies marginalization and ‘hardening’ of PWUD (Coumans et al., 2006). Additionally, 
when enforcement removes key participants from the illicit drug market, rather than permanently 
hurting the market, it creates turnover and opens profitable opportunities (Werb et al., 2011). 
Another negative effect of enforcement is that it can deter PWUD from using harm 
reduction strategies. When PWUD fear police interactions, they are more likely to use drugs in 
isolated, unsafe places. In their haste, they are more likely to skip important steps like using 
NSPs and sterilizing the injection site (Beletsky et al., 2014; Bozinoff et al., 2017; Kerr et al., 
2005). A United Nations report stated that criminalization, discrimination and punitive law 
enforcement practices discourage people who are dealing with HIV and substance dependence 
from accessing HIV and health care services, thereby perpetuating the spread of HIV (United 
Nations General Assembly, 2011). 
 Harm reduction, by its philosophy, does not include practices that increase risk to 
individuals and communities. Critics of harm reduction express concern that it enables or 
promotes drug use (Potier et al., 2014). However, in communities where SIFs have opened, 
evidence shows that there have been no increases in crime, drug use, drug trafficking, the 
number of people who use drugs, and the number of people switching from non-injection drug 
use to injection drug use (Potier et al., 2014; Wodak & Cooney, 2005). Moreover, research 
following the opening of Vancouver’s SIF found no evidence of increased injection drug relapse 
rates, and no change in drug use cessation rates (Kerr et al., 2006).  Harm reduction has not 
increased the drug related problems of PWUDs and surrounding communities as tough-on-crime 
drug laws have. 
Economics. In the few instances where enforcement and criminalization drug control 
models have been reviewed, they have been found costly and ineffective at reducing problematic 
GUIDELINES TO DESTIGMATIZE HARM REDUCTION WORK   !! $%!
drug use (UK Home Office, 2014; Zábransk!, 2004). A consequence of scaling up enforcement 
as a means of drug control in the U.S. has been the immense increase in prison populations and 
the resulting high cost on taxpayers (Werb et al., 2011). Countries and states that have 
decriminalized cannabis saved substantial amounts in criminal justice costs (Global Commission 
on Drug Policy, 2016). Portugal reduced social costs by 18% over ten years after decriminalizing 
all substances, partly due to PWUD being able to continue working rather than being 
incarcerated (Goncalves, Lourenco & da Silva, 2015). 
 Cost benefit analysis of harm reduction programs have shown them to be highly cost 
effective. HIV prevention strategies such as NSPs, SIFs and OATs, cost less than HIV treatment 
(Pinkerton, 2011; WHO et al., 2004). Due to their impact on reducing illicit opioid use, OATs 
contribute to additional savings by decreasing relapse, incarceration, and enforcement costs 
(WHO et al., 2004; Wilson et al., 2015). Reductions in criminal activity and health care costs are 
the greatest economic benefits of harm reduction services (McCollister & French, 2003). 
 Social justice and human rights. In 2015, after completing a study on the impact of the 
world drug problem on human rights, the UN High Commissioner for Human Rights concluded 
that drug policy, law and enforcement have led to a number of human rights violations such as 
discrimination and unjust treatment of PWUD, and excessive arrests, detention and incarceration 
for minor drug offences. He also denounced inhumane treatment of PWUD in institutional 
settings, denial of life-saving health care for PWUD, and restrictive access to opioids for pain 
and health management among PWUD (UN High Commissioner for Human Rights, 2015). Such 
violations of human rights damage respect for the rule of law and create contempt, suspicion and 
fear of those who enforce it (Chaney & Robertson, 2013). 
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 Human rights considerations are the core of harm reduction services. Harm reduction 
does not aim to criminalize or stigmatize human behaviour, rather it seeks to empower people by 
supporting autonomy in managing their levels of risk. In 2011, when the federal government 
wanted to shut down Canada’s only operating SIF, Insite, the Supreme Court ruled unanimously 
that doing so would be a violation of human rights to life, liberty and security (Canadian 
HIV/AIDS Legal Network et al., 2015). The court stated that the government’s decision to refuse 
an exemption to Insite undermined the health and safety mandate of Canadian drug laws because 
the health benefits that the facility provides to PWUD and the surrounding community outweigh 
any benefits of upholding prohibition laws. The court further ruled that access to prevention 
services and life-saving services cannot be denied for the sake of upholding prohibition laws, and 
that to do so would be an inexcusable violation of rights to people most in need of public 
services (Canadian HIV/AIDS Legal Network et al., 2015).  
 Disproportionate negative outcomes. An unacceptable problem evident in the research 
on enforcement drug control is that it disproportionately punishes certain demographics. 
Between 2007 and 2016 the federal prison population in Canada increased by less than 5%, 
while the Indigenous prison population increased by 39%. Furthermore, Indigenous people 
account for less than 5% of the Canadian population, but comprise 26.4% of the federal inmate 
population (Office of the Correctional Investigator of Canada, 2017). These grossly 
disproportionate statistics are directly impacted by drug policy. As the Office of the Correctional 
Investigator of Canada (2013) reports, the high incarceration rates of Aboriginal peoples is 
associated with systematic discrimination, substance use and intergenerational trauma, among 
other factors. 
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 America’s black population accounts for 13% of the population, uses drugs at 
comparable rates as other populations, make up 29% percent of those arrested for drug law 
violations, and account for 40% percent of the federal inmates with drug-related charges. Latinos 
comprise 18% percent of the American population, 47% percent of all federal court drug offence 
case, and 38% percent of federal inmates arrested for drug-related offences (Drug Policy 
Alliance, 2018) 
 These statistics understandably cause suspicion around whether the aim of the war on 
drugs was ever to deter harmful drug use, or whether it offered a convenient way to disempower 
certain groups. Harm reduction, on the other hand, is anti-oppressive in that it seeks to empower 
people with education and choices regarding their substance use.  
Barriers to Evidence Based Drug Policy 
 Despite the clear evidence in support of harm reduction, it remains a contentious issue 
globally and in Canada.  International coverage of harm reduction services remains low where 
there is urgent need to scale up (Mathers et al., 2010). Harm Reduction International (2016) 
estimates that there is significant injection drug use in 158 countries, but only 90 with 
operational NSPs.  Countries with little to no harm reduction services in Eastern Europe and Asia 
continue to see rising HIV rates from injection drug use while global incidences of HIV infection 
have been on the decline (UNAIDS, 2015). 
 A 2017 study by the Canadian Harm Reduction Policy Project reviewed the status of 
harm reduction services in Canada and concluded that provinces and territories are lacking 
consistent comprehensive governance outlines for optimal use of harm reduction strategies. 
(Wild, et al., 2017).  Health service providers have criticized the lack of effective harm reduction 
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in legislation and note that there is too much political, as opposed to evidence-based, influence 
on public health issues (Canadian Nurses Association, 2012).   
A question that comes up repeatedly in the literature is that with all the supporting 
evidence demonstrating the effectiveness and cost effectiveness of harm reduction, as well as the 
evidence outlining the harms and deficiencies of enforcement drug control, why is it so 
challenging to shift towards a better model of drug policy?  Outlined below are explanations of 
the unique challenges around moving towards evidence-based drug policy. 
 Public opinion, politics and press. Understanding why evidence bears so little influence 
on drug policy requires an examination of the interactions between politics, the media, and the 
public.  Public opinion has a significant impact on policy (Burstein, 2003). With politically 
salient issues, public opinion has greater influence than evidence (Monroe, 1998; Page & 
Shapiro,1983).  When it comes to harm reduction, political motivation to institute and maintain 
these services is significantly swayed by public perceptions of harm reduction (Rapid Response 
Service, 2012). However, public opinion is largely influenced by the media, and by politics 
through the media (Blendon & Young, 1998; Millhorn et al., 2009; Shanahan, Mcbeth & 
Hathaway, 2011). The U.S. government has been found to have spent over a billion dollars on 
years of media propaganda effort that justify tough, drug war policy (Boyd, 2002). Governments 
and media have been fueling the need for a war on drugs for over a century by vilifying the illicit 
drug scene and painting those involved as evil predators seeking to destroy lives of the young 
and innocent (Benso, 2010; Coomber, 2010).   
The philosophy of harm reduction that humanizes PWUD, and seeks to decrease the 
harms of their behaviors, is at odds with the historic view that they deserve punishment through 
tough-on-crime law enforcement. It is understandable, though problematic, that dated narratives 
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ingrain ways of thinking that become inflexible to conflicting evidence, and strengthened by 
ongoing misinformation. For instance, the president of the U.S. has recently claimed that 
countries with harsher, tough-on-crime drug control have had the most success dealing with the 
problem of drug use (Meza, 2018). His sentiment was likely taken as fact by millions of people 
despite it being in direct opposition with the evidence.  
 Canada’s changing political climate since the 2015 election is more favourable towards 
evidence-based drug policy, but politics continue to counter evidence. The Prime Minister has 
expressed support for SIFs (Lupick, 2015) and the government has changed legislation to make 
legality issues around SIFs less restrictive (Kerr, 2017). However, the federal government’s 
moves towards evidence-based drug policy continues to be fought by the opposition who have 
been accused of perpetuating the controversy and fear surrounding drug policy as a platform to 
gain votes (Kassam, 2018).  
 Morality policy. Wild et al. (2017) offered an explanation to the question around the 
difficulty of translating evidence to policy, suggesting that the contested nature of harm 
reduction is an issue of morality policy, or policy that is based on core values and notions of 
right and wrong. They explain that this morality context of drug policy is what makes it resistant 
to arguments based on health and economics research. Reuter (2001) reasoned in the same vein 
that drug use has historically been presented as a problem of crime and morality, so the logic in 
treating it as a problem of health and addiction is lost in justice considerations of right and 
wrong. In a morality policy context, research for effectiveness and cost benefit analysis are 
irrelevant if the aim of enforcement is to bring criminals to justice. Blendon and Young’s (1998) 
research on American attitudes towards the war on drugs support this concept. They found that 
most Americans do not think the war on drugs has been successful, but they do not wish to 
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change these efforts. Furthermore, they see drug use as a moral issue, not a health issue. 
Research from the U.K. suggests that polarizing moral issues around drug policy prevent 
productive discourse about the goals of drug policy, and therefore prevent new directions for 
drug policy reform (Singleton & Rubin, 2014). 
 Dismissed Evidence. Evidence that is not seen or understood can have little impact on 
policy. The research team in Toronto that was responsible for assessing the need for SIFs had 
established a thorough evidence base on the positive health and social benefits of SIFs, but the 
main discussion around drugs in the media was on the rapid increase in fatal opioid overdoses 
during the ongoing opioid crisis (Bayoumi & Strike, 2016). A U.K. review on good governance 
of drug policy found that public debate on drug policy, as fuelled by the media and questionable 
evidence, is focused on disagreement over the harms of illicit substances as opposed to a sensible 
response to these harms. It further stated that expert opinions of the Advisory Council on the 
Misuse of Drugs is often rejected, highlighting a problem of undervaluing research in policy 
decisions (Singleton & Rubin, 2014).  
 Even when the general population is exposed to research that supports harm reduction, 
their preexisting notions about illicit drug use, and lack of experience with health research can 
skew their understanding of the information. Reuter (2001) explains that a 25% decrease in 
future heroin use may be a promising reason for researchers to endorse a given treatment 
program, but the lay observer may be put off by the fact that the immediate beneficiary of the 
program will be people who are criminals due to their drug use. Additionally, the public may 
note that most people using the program will continue to use drugs in some capacity, a result that 
may seem problematic without a background understanding of the economic and health benefits 
of harm reduction. 
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Public Perceptions 
 A reoccurring topic in the literature on the barriers to implementing evidence-based 
policy is public perceptions of drug use and drug policy. It is widely accepted that politicians are 
avoidant of endorsing research that contrasts with the prevailing views of the press and public 
within their support base (Monroe, 1998; Page & Shapiro,1983; Singleton & Rubin, 2014). 
However, the literature on public support is unclear because statistics show high support for 
harm reduction, yet the stigma that exists towards PWUD is well documented.  The general 
stigma towards drugs and PWUD may be diminishing existing support for harm reduction, and 
negatively impacting the provision of harm reduction services. 
 Public support. In Canada, surveys and studies completed between 2003 and 2007 on 
public perceptions and support for harm reduction show a majority support for harm reduction 
programs. These polls, surveys and studies were from B.C., Quebec, Ontario, and nation-wide, 
and they include support for NSPs, and heroin-assisted treatment (HAT) (Rapid Response 
Service, 2012). A 2013 study of public attitudes towards safer drug use practices in B.C. found 
76% support for harm reduction in general, 72% for NSP, 65% for NSP in their local 
community, and 52% for safer inhalation equipment (Tzemis et al., 2013). Cruz et al. (2007) 
completed a study of public opinions towards harm reduction practices, and found 60% support 
for SIFs and HATs in Ontario. Survey results posted in 2017 show the differences in community 
support for SIFs in major Canadian cities. Vancouver, Ottawa, Toronto and Montreal show 
majority approval ratings. The three lowest levels of approval came from the prairies with 
roughly 40% approval, 40% disapproval and 20% unsure in Calgary, Saskatoon and Regina 
(Duggan, 2017). A 2016 study in Ontario showed a different perspective. When given the 
options to strongly agree, strongly disagree, or somewhat agree and disagree that certain harm 
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reduction services should be made available, the majority expressed the ambiguous response. 
60% of respondents somewhat agreed and disagreed with SIF availability and 64% expressed the 
same for supervised smoking facilities (SSF). For SIFs, 28% strongly agreed, and 12% strongly 
disagreed, compared with 20% that strongly agreed, and 16% that strongly disagreed with SSFs 
(Strike, Rotondi, Watson, Kolla & Bayoumi, 2016). This study examined public support for 
different goals of harm reduction such as safer drug use, reduction of infectious diseases, reduced 
drug-related neighbourhood problems, or increased contact between PWUD and health and 
social services. Support was strongest when the goals of the facilities were about reducing drug-
related problems in the neighbourhood. In this case, 56% strongly agreed with SIFs, and 46% 
strongly agreed with SSFs. Another result from Strike et al. (2016) was that the lack of harm 
reduction services available for inhaled stimulates, such as crack cocaine and 
methamphetamines, compared to the services available for injection drug use, was parallel with 
how many Ontarians were aware of SSF models - 20%, compared with about 60% awareness of 
SIF services. The outcome of this research suggests that raising awareness of the benefits of 
harm reduction services, especially those relevant to the broader community, may increase 
support and expansion of services. 
Internationally, a 2012 review of public opinions and perceptions of harm reduction 
found that most studies and surveys were from Canada, the U. S., the U.K., and Australia, and 
the results show a majority in support of various harm reduction services (Rapid Response 
Service, 2012). In Sydney Australia, businesses and residents located within the vicinity of NSPs 
indicated 83% support for NSPs in general, and 77% support for local NSPs.  Support for a 
newly established syringe automatic dispensing machine was slightly lower at 67% in general 
and 60% locally. When asked about common concerns about harm reduction services, less than 
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half of the participants endorsed concerns such as increased number of injection drug users, and 
increased number of drug-related crime in the neighbourhood.  Five years after the establishment 
of a SIF in Sydney, local residents and businesses reported seeing less public injection drug use, 
less publicly discarded needles and less drug-related public nuisances. There was no significant 
trend in amount of residents who were offered drugs for purchase in the streets (Salmon et al., 
2007). Both of these studies show that a majority of the local residents and businesses who took 
part in this research see the benefits of harm reduction in their local neighbourhood and do not 
endorse fears about increased drug-related problems. 
In the U.S., a 2015 study showed 81% of participants somewhat to strongly supported 
NSPs, and 60% somewhat to strongly supported SIFs (Kulesza et al., 2015).  Two decades ago, 
Blendon and Younge (1998) researched American attitudes towards policies established under 
the war on drugs mentality. They found a slight majority support for NSPs when told that these 
services were endorsed by the American Medical Association. It is important to note that results 
on the topic of harm reduction are influenced by wording, design, and the organization 
commissioning the study (Hopwood, Brener, Frankland, & Treloar, 2010). Surveys conducted by 
organizations with a public health mandate were more likely to show results that support NSPs 
than surveys run by organizations with a family values focus (Vernick et al., 2003).  The one 
study included in this literature review that found a minority support for harm reduction was one 
that framed the concept of support in terms of willingness to pay. The response showed 43.2% in 
favour of allocating tax dollars to NSPs, and 39.4% towards methadone treatment (Matheson, 
2014). 
 Public resistance. The statistics in public perceptions outlined in the section above are 
mostly positive, yet harm reduction remains a highly contentious topic that receives vocal 
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political and public opposition. Tzemis et al. (2013) noted that even in municipalities in B.C. that 
responded with a majority support for harm reduction, the policies did not reflect supportive 
attitudes. They noted that some municipalities in the Fraser Health Authority region had bylaws 
in place prohibiting harm reduction services despite respondents from this region showing 69% 
support. Another municipality on Vancouver Island with a 78% support response within their 
health authority had recently closed down a twenty-year-old NSP. These findings suggest that 
the policy makers in these two cases may have been responding to a vocal minority whose views 
may have been generalized to the broader public. White et al. (2016) noted a similar situation in 
Sidney Australia wherein national data indicated majority support for harm reduction, yet the 
implementation of their first syringe automatic dispensing machine was met with apparent 
community opposition in media reports. Likewise, Salmon et al. (2007) found that businesses 
and residents in Sidney expressed awareness of the benefits that a local SIF brought to the 
community while political controversy surrounding the opening of the SIF was ongoing. 
Stigma and discrimination. Perhaps it is not surprising that public opposition, even a 
minority, would be so strong since stigma around drug use remains prevalent. The stigma 
towards drug use and PWUD is a major factor in public support for harm reduction (Cruz et al., 
2007; Kulesza et al., 2015). Common concerns about harm reduction services include attracting 
more PWUD to the areas of service availability, increasing drug-related crime and public 
nuisances, and the belief that harm reduction promotes or condones drug use (Potier et al., 2014; 
Wodak & Cooney, 2005). When describing opposition to a methadone clinic in Toronto, Smith 
(2010) summarized community concerns by likening the body of an ‘addict’ to an infection, and 
the clinic to a site of contagion. Blendon and Young (1998) reported that among America’s 
highest concerns about illicit drug use are increased crime rates and a diminished national image. 
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Criminalization of certain substances and the war on drugs have made stigma and 
marginalization of PWUD socially acceptable (Ahern, Stuber & Galea, 2007; Earnshaw, Smith 
& Copenhaver, 2013). Discrimination against those seen as deviant or criminal is so normalized 
in society that it can go unnoticed. In a study on “not in my back yard” patterns of resistance 
towards harm reduction, the authors termed the stigma and discrimination that they found 
towards PWUD an “inequitable exclusion alliance” wherein these oppressive attitudes towards 
vulnerable populations is institutionalized by politicians and the law (Tempalski, Friedman, 
Keem, Cooper & Friedman, 2007). 
Surveys and vignette design studies provide evidence that PWUD are seen as 
unpredictable and dangerous.  Their willingness to engage in risky behaviour is seen as immoral. 
Their dispositions are seen as their fault, and therefore their suffering is self-inflicted and 
perhaps deserved. This stereotypic perception of PWUD is associated with less pity and helping 
behaviour, and more avoidance, fear and anger (Corrigan, Kuwabara & O’Shaughnessy, 2009; 
Crisp, Gelder, Rix, Meltzer & Rowlands, 2000; Lee & Rasinski, 2006; Sattler, Racine & Göritz, 
2017). Even family members of people with substance use disorders endure blame and social 
shame for their perceived role in the matter (Corrigan, Watson & Miller, 2006). Stigma around 
drug use justifies more punitive rather than help-based responses to people with substance use 
disorders. Lee and Rasinski’s (2006) research on the American social justice system found that 
the amount of blame and moral judgment put on PWUD for their drug use or addiction was 
positively correlated with the severity of sanctions. (Lee & Rasinski, 2006).   
PWUD have been known to avoid health and social services because of the 
discrimination and abusive law enforcement practices they may encounter in certain public 
spaces (United Nations General Assembly, 2011). A 2017 Canadian participatory research study 
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explored the preferences, experiences, and reasons for engaging in harm reduction among 
PWUD. The most commonly noted barrier that was not specific to service parameters, such as 
rules and availability, was the “pervasive anti-drug discrimination and stigmatization in society 
at large” (Boucher et al., 2017, p.11). Vancouver’s Downtown Eastside has a number of harm 
reduction services available including the only operating SIF in Canada for 15 years, until recent 
changes in legislation allowed more SIFs to open in 2017 (Kerr et al., 2017). Street-involved 
youth reported wanting to leave or avoid this area because of the stigma associated with it, even 
though this meant engaging in higher risk drug use (Bozinoff, 2017).  This is in line with 
Anstice, Strike and Brands’ (2009) research with clients of Canadian methadone clinics who 
reported concern about being seen entering or leaving clinics. Some clients said they preferred 
using pharmacies for this reason, yet respondents also described feeling more stigma and 
embarrassment at pharmacies than at methadone clinics because the later was seen as more 
catered towards PWUD. 
In health care, negative perceptions of PWUD are common and problematic.  PWUD 
have reported that despite their efforts to adopt harm reduction practices into their routines, they 
felt negative judgment, disrespect, condescension, and rejection from health service providers 
(Boucher et al., 2017). The most common stereotypes endorsed by nurses regarding PWUD are 
that they have weak character and are violent, dangerous, unhygienic, infected and contagious 
(Natan et al., 2009). Pauly (2008a) identified what he called value tensions among nurses. The 
tensions were about not being able to “fix” people with addiction problems, and believing that 
PWUD were at fault for their addiction and inability to recover. These tensions resulted in 
PWUD being seen as a waste of time and resources, and being less deserving of care than 
patients with health issues that have less personal responsibility ascribed to them (Pauly, 2008a). 
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These kinds of attitudes are in direct conflict with the ethical responsibility to provide equal care 
to all in need (Canadian Nurses’ Association, 2008). A systemic review of stigma towards 
PWUD among health professionals found that common stigmatizing beliefs in health care are 
that PWUD can be violent, manipulative, untrustworthy, and poorly motivated. Holding these 
negative views of clients resulted in professionals feeling frustration, resentment, and 
powerlessness, and they reported less motivation and job satisfaction when working with PWUD 
(Van Boekel et al., 2013).  
Implications of Stigma on Health and Well-Being 
Stigma towards PWUD is a normative and accepted part of our culture, largely due to the 
criminalization of illicit drug use. As long as PWUD are perceived as criminals, they will be 
more likely to be seen as deviants of society, untrustworthy, dangerous, unpredictable and 
undeserving, as many of the studies in this review have shown (Ahern et al., 2007; Corrigan et 
al., 2009; Crisp et al., 2000; Earnshaw et al., 2013; Lee & Rasinski, 2006; Sattler et al., 2017; 
Tempalski et al. 2007). The implications of stigma on health, social worth and self-concept are 
reviewed below. 
Suboptimal health care outcomes. The negative attitudes of health professionals 
outlined in Van Boekel et al. (2013) resulted in more avoidant delivery of services to PWUD 
compared to other patients. This meant shorter visits, less empathy, diminished personal 
engagement, a more task-oriented approach, and reduced collaboration between professionals 
and patients.  The lack of trust in PWUD is exemplified in the account of a research participant 
who had her prescription for stabilizing pain medication, which she had been taking for years, 
withheld from her because other drugs had been found in her system (Boucher et al., 2017). 
Pauly (2008a) found evidence that care was being rationed so that less time was spent with 
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patients considered more to blame for their health concerns and less deserving of care due to 
their social status.  This tangible difference in treatment can reduce client self-esteem and 
empowerment, thereby negatively impacting treatment retention and outcomes (Anstice, Strike 
& Brands, 2009; Curtis & Harrison, 2001). The takeaway finding from research on this topic is 
that stigma and discrimination in health care contributes to suboptimal delivery of care to 
PWUD. 
 Decreased health and well-being.  Meta-analyses show that stigma and discrimination 
are associated with increased prevalence of mental health challenges among stigmatized groups 
(Mak, Poon, Pun & Cheung, 2007; Pascoe & Richman, 2009). The stigma and discrimination 
related to having a devalued social identity, such as having a substance use disorder, can feel 
threatening to the individuals impacted.  As a result, perceived or anticipated stigma can lead to 
heightened physiological and behavioural stress reactions which negatively impact performance 
(Blascovich, Mendes, Hunter, Lickel & Kowai-Bell, 2001), and are related to increased 
unhealthy coping and decreased healthy coping behaviours (Pascoe & Richman, 2009). Among 
people in treatment for substance use, perceived stigma was associated with poor sleep, 
increased depression and anxiety, and lower self-esteem (Birtel et al., 2017). PWUD report a 
high amount of stigma from those closest to them, friends and family (Earnshaw, Smith & 
Copenhaver, 2013).  Perceived stigma from close connections diminishes the quality of 
interpersonal relationships and decreases perceived social support, which is integral to recovery 
and wellbeing (Gyarmathy, & Latkin, 2008; Thoits, 2011). 
 Oppression and inequality. Corrigan and Wassel (2008) describe three ways of 
experiencing stigma, and forms of discrimination and oppression that each result in. Their 
research on three forms of stigma are outlined below. 
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 Public Stigma. For some PWUD, their addiction is visible. A disheveled appearance is a 
common stereotype. Even those in recovery who may have limited access to housing and 
hygiene may receive judgment from others who assume they are a “junkie”. Stigma for visible 
traits that are associated with addiction can lead to missed opportunities such as access to 
housing, jobs, social services, insurance coverage and treatment (Corrigan & Wassel, 2008). 
Common disadvantages experienced by PWUD include social rejection and isolation, 
psychological distress, inadequate health care, difficulty finding employment, and denial of 
important responsibilities by employers (Crisp et al., 2000; Earnshaw et al., 2013). 
 Self-stigma. When a person is aware of the negative judgments and stereotypes put on 
them due to a devalued social identity, they are more likely to internalize these stereotypes as 
indicators of decreased worth. Perceived stigma negatively impacts mental health by confirming 
and strengthening self-stigma (Birtel et al., 2017). Loss of self-esteem and self-efficacy can 
decrease motivation, and lead to a defeated disposition towards wellness and opportunities.  
(Corrigan & Wassel, 2008). Lago et al. (2017) argued that internalized stigma decreases self-
trust, and that without self-trust, a person cannot experience complete autonomy. In these ways, 
stigma towards mental health and substance use disorders is a barrier to personal growth and life 
aspirations. 
 Label Avoidance. Prejudice and discrimination associated with labels, such as diagnosis 
or perceived mental health problems, can motivate people to avoid situations where they may be 
labeled. This can mean avoiding professional assessment and treatment that may confirm a label 
or make it visible to others (Corrigan & Wassel, 2008). It may also lead to keeping an addiction, 
or other mental health challenge, private. Strategies for privacy can lead to isolation and 
GUIDELINES TO DESTIGMATIZE HARM REDUCTION WORK   !! %*!
diminished social support due to avoidance of social interactions, and increased negative coping 
behaviours for dealing with stigma (Link et al., 1989).  
The socially accepted stigma towards PWUD is not just punitive for perceived criminal 
behaviour, it is oppressive of their growth, identity and quality of life.  
Addressing Stigma in Harm Reduction and Health Services 
 The experience of stigma in health care settings contradicts goals of health and wellness. 
The unequal power dynamics between those providing services and those seeking services is 
increased when those seeking services are a socially devalued group. Unequal power dynamics 
strengthen the negative impact of stigma on the disadvantaged group (Johnson, 2006). The result 
is a health care system that plays a role in perpetuating diminished hope and motivation towards 
wellness for people with substance use disorders. This form of institutionalized oppression is 
challenging, but possible, to change. 
 Awareness of the benefits of harm reduction, especially those relevant to the community 
as a whole, increases community support for harm reduction practices (Strike et al., 2016). 
Changing stigmatizing beliefs about PWUD can both reduce discrimination against this group, 
and allow for meaningful discussions about evidence-based harm reduction strategies (Kulesza et 
al., 2015).  Lago et al. (2017) recommend public educational initiatives on the social systems that 
oppress PWUD, as well as continuing education for health professionals on ethical practice 
around this topic. Anstice et al. (2009) reported that reducing stigma in harm reduction service 
environments may improve meaningful service accessibility, and improve treatment outcomes.  
The research included in this review on community perceptions of harm reduction and 
PWUD has been assembled into an educational guidebook for destigmatizing harm reduction 
(see Appendix for guidebook).  It incorporates research findings on the experiences of PWUD, 
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common stigmatizing beliefs, and suggestions for reducing stigma. The guidelines and a rational 
for each one are outlined below. 
People who use drugs are deserving of services, their lives have value. This section 
addresses the issue of PWUD being seen as social problems who are less deserving of care than 
other patients (Boyd, 2017; Pauly, 2008a; Van Boekel et al., 2013). It addresses the human right 
of equal access to health care. Kulesza et al. (2015) found that shifting perceptions of PWUD to 
being deserving of help rather than punishment increased positive attitudes towards harm 
reduction. When challenging stigma towards PWUD, it is important to not only target negative 
beliefs, but to highlight positive attributes. This section highlights the activism work that PWUD 
have contributed to drug policy and human rights issues.  
Successful harm reduction does not require healing addiction. A problem identified 
in health care is an ideology of “fixing” that causes health professionals to give up on patients 
whose mental health and substance use issues are complex and not easily remedied (Pauly 
2008a). Many people engage in a range of harm reduction practices for reasons such as 
prevention or management of infectious disease, reducing risk behaviours, social support from 
staff and peers, counselling service availability, and a comfortable welcoming space (Boucher et 
al., 2017). Understanding that decreasing risk and enhancing support in service environments is 
successful work that promotes ongoing service use may decrease frustration and resentment 
among health care providers (Pauly 2008a; Van Boekel et al., 2013). 
Be critical of social contexts that oppose goals for positive change. Corrigan and 
Wassel’s (2008) work on different forms of stigma provides an outline on how societal stigma, 
internalized stigma and stigmatized labels impact options and opportunities for housing, 
employment and treatment. They also illustrate how the experience of stigma reduces social 
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support, self-worth and motivation towards change. Lago (2017) argues that when internalized 
stigma leads to self-trust issues, it limits full autonomy of the individual to make and follow 
through with positive choices. Understanding more about how normalized negative perceptions 
of PWUD impact client care and well-being may help health professionals redirect critical 
beliefs about their clients towards critical thought about the social oppressions that limit clients, 
as well as their professional role in that process. 
Strengthen decision-making capacity, and avoid persuasion. When client goals differ 
from those of health professionals, tensions and judgments may arise. Research in a drug 
treatment setting found that health professionals were unintentionally imposing their beliefs, 
values and prejudices on clients in their care, and that doing so had a disempowering effect on 
clients (Curtis & Harrison, 2001). To counter disapproving attitudes towards clients, nurses 
focused on a common goal of enhancing client decision-making capacity. They recognized 
clients’ responsibility for their choices but also recognized the limitations many clients’ life 
circumstances provided for developing decision-making capacity (Pauly, 2008a). 
Support general life goals, as well as managing risk behaviours. PWUD reported that 
when the focus of harm reduction services and health professionals is restricted to mediating risk 
behaviours, it feels as though the services are for public interest in reducing disease transmission 
and discarded needles, rather than for the individuals using the services. They expressed having 
additional reasons, beyond the mainstream focus on public safety issues, for choosing harm 
reduction practices. Their reasons include maintaining social relationships, accessing social 
services, counselling support, and the pursuit of general life goals (Boucher, 2017). When harm 
reduction is focused only on risk management, and not social support, it is insufficient at meeting 
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the needs of clients who face intersectional inequalities such as poverty, homelessness, and 
limited access to health care (Pauly, 2008b). 
Harm reduction is not supporting substance use, it supports people and 
communities. The Ontario HIV Treatment Network made a list of recommended educational 
efforts to change negative opinions about harm reduction and PWUD (Rapid Response Service, 
2012). Among their recommendations was the importance of making sure the public understands 
that harm reduction does not equate to condoning or promoting drug use. This section of the 
guidebook illustrates the benefits of harm reduction for PWUD and communities. Especially 
when contrasted to the harms of criminalization and enforcement, harm reduction practices are 
the best evidence-based strategies available for decreasing problems associated with substance 
use. Understanding this may decrease problems of low motivation and morality issues 
experienced by professionals working with PWUD. 
Harm reduction is not a waste of tax dollars and health services. Misperceptions 
about harm reduction lead to common concerns about allocating money and resources towards 
drug use (Matheson, 2014). Research outlining the economic benefits of harm reduction, 
especially in contrast with social justice costs, may decrease concerns about misperceptions that 
PWUD are draining health care resources. 
 Support, trust and advocacy are valued and impactful. Research on the benefits of 
supportive relationships on health care outcomes for PWUD, as well as appreciation expressed 
from PWUD about their positive experiences with services providers, may decrease feelings of 
powerlessness, resentment, low motivation, and low satisfaction among health professionals 
working with this demographic (Van Boekel et al., 2013). Perceived social support is associated 
with higher self-esteem, better sleep, and lower depression and anxiety among PWUD (Birtel et 
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al., 2017). This guideline is meant to inspire qualities such as warmth and understanding that 
contribute to positive and meaningful relationships between services providers and PWUD 
(Earnshaw et al., 2013).  
 Take care, debrief and seek support. Harm reduction and health care work with PWUD 
is known to be challenging on professionals for reasons including burnout, secondary trauma and 
discouragement (Shepard, 2013; Van Boekel et al., 2013). Work environments impact health 
professionals’ attitudes towards PWUD. Organizational support such as supervision and 
consultation opportunities contribute significantly to increased job satisfaction and willingness to 
work with PWUD. Additionally, supportive work environments increased self-esteem, perceived 
knowledge and feelings of empowerment among care providers (Van Boekel et al., 2013). This 
guideline encourages health professionals to utilize their supports, and to optimize their work and 
home environments. 
Summary of Part Two 
 Despite the wealth of research supporting harm reduction drug policy, outdated drug 
control measures, as well as stigma around drug use and PWUD, have been major barriers in 
shifting drug policy towards evidence-based practices in Canada. Stigmatization and 
discrimination of PWUD have led to harm reduction service avoidance, treatment avoidance, 
subpar delivery of health care, and ongoing oppression of this group that limits their access to a 
range of personal wellness aspirations. Research on community attitudes towards PWUD brings 
attention to specific stigmatizing beliefs such as the perception that they are more deserving of 
punishment than help, and that they are more at fault for their health issues than other people, 
thereby less deserving of treatment and support. Research also identifies negative beliefs and 
misperceptions about harm reduction such as the fact that it’s using tax dollars to support 
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criminals. Suggestions for decreasing societal stigma towards PWUD include shifting from 
punishing substance use towards decreasing harms of substance use, focusing on the common 
values of human rights rather than moral differences, and accepting the reality that substance use 
is a societal issue and not just an individual problem. Since research is not often widely reviewed 
by the public at large, or even accessible to them, a summary of this information has been made 
into a guidebook that can be used as a practical tool to combat stigma in health care settings and 
in the broader community.  
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Part Three: Project Description 
The following project is a guidebook on destigmatizing harm reduction work. It includes 
guidelines that challenge stigmatizing beliefs about PWUD, and misperceptions about harm 
reduction. It is based on recommendations for addressing stigma from a literature review on 
public perceptions of harm reduction and PWUD. Part three will provide an overview of the 
guidebook target audience, its goals and objectives, and a step-by-step process of how it was 
made. See Appendix for the complete guidebook. 
Target Audience 
 Since research identifies discrimination and stigmatization in health care as a barrier to 
optimally making use of harm reduction services, the target audience for this project will be 
people who work in the field of addiction and substance use services under a harm reduction 
mandate. This includes a range of health care professionals such as people working in hospitals, 
clinics, pharmacies, mental health services, needle exchanges, safe injection facilities, and people 
doing outreach work. 
This guidebook may be used by organizations that offer addiction and harm reduction 
services as part of staff orientation, training, or as optional educational material. It may also be 
used by students in relevant fields of study such as social work, phycology, and political science. 
Additionally, it may be distributed to the general public by any organizations or individuals such 
as addiction services, doctor’s offices and activist groups that are interested in supporting harm 
reduction and PWUD. 
Guidebook Goals and Objectives 
 The main goal of this project is to decrease stigma towards PWUD in harm reduction 
health care services. A secondary goal is to increase job satisfaction for health care providers in 
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the field of harm reduction and addiction. These goals are based on the problem of stigma and 
discrimination towards PWUD in health care services, and a contributing factor to this problem, 
the negative attitudes of health professionals towards PWUD (Anstice et al., 2009; Pauly, 2008a; 
Van Boekelet al., 2013). The project offers a set of guidelines for meeting these goals. See Table 
I below for the complete list of guidelines. 
Table I 
 
Guidelines for Destigmatizing Harm Reduction 
 
People who use drugs are deserving of services, their lives have value. 
 
 
Successful harm reduction does not require healing addiction. 
 
 
Be critical of social contexts that oppose goals for positive change. 
 
 
Strengthen decision-making capacity, and avoid persuasion. 
 
 
Support general life goals, as well as managing risk behaviours. 
 
 
Harm reduction is not supporting substance use, it supports people and communities. 
 
 
Harm reduction is not a waste of tax dollars and health services. 
 
 
Support, trust and advocacy are valued and impactful. 
 
 
Take care, debrief and seek support. 
 
 
 The guidebook has five objectives, the first of which is confronting stigmatizing beliefs 
and discriminating actions directed at PWUD. Second, it aims to raise awareness and 
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understanding of how stigma impacts health and wellness outcomes. The first two objectives are 
met by outlining research findings on the topic of public perceptions towards people who use 
drugs. Case examples are included to exemplify the problems each guideline aims to address. 
The third objective is to increase understanding of what harm reduction is and whom it serves. It 
does this by challenging common misperceptions about harm reduction with evidence of 
effectiveness. Fourth, the guidelines promote behaviours that decrease stigma, and support health 
and wellness outcomes for PWUD. The final objective is to empower service providers towards 
actions associated with improved job satisfaction. The guidebook meets the last two objectives 
by including ‘Take-away Message’ sections that suggest ways of applying each guideline to 
health care work. 
How it was Made 
This project is based on a literature review on the topic of community attitudes towards 
harm reduction. The stigmatizing beliefs and practices identified in the literature review, as well 
as the recommendations for decreasing stigma, have been organized into guidelines for the 
purpose of creating an evidence-based guidebook on how to destigmatize harm reduction work. 
A step-by-step process for how it was made is outlined in Table II below. A screenshot of an 
excel spreadsheet is shown in Figure 1 to exemplify how excel was used in step two to organize 
research notes.  
Table II 
 
Steps Included in Making the Guidebook  
 
Step 1 
 
 
Literature review was completed on community attitudes towards harm 
reduction and PWUD 
 
 
Step 2 
 
Collected research findings that: 
• identify misinformed perceptions of harm reduction 
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• identify stigmatizing beliefs about addiction and people who use 
drugs 
• recommend strategies for increasing support for harm reduction 
• recommend strategies for decreasing stigma towards harm 
reduction and people who use drugs 
 
Step 3 
 
• Organized the research from step two into categories using Excel 
spreadsheets. 
• Refined notes by collapsing similar themes and removing those 
not relevant to the goals of the project. 
• Summarized the research findings into a set of nine guidelines 
for destigmatizing harm reduction work. 
 
 
Step 4 
 
An explanation of each guideline was written and organized into four 
sections: 
• Key issue – to describe the purpose of the guideline 
• Background information – to provide a rational for the guideline 
and outline the research it’s based on 
• Case examples – to provide scenarios that exemplify the 
problem being addressed by the guideline. 
• Take-away message – to suggest ways of applying the guideline 
to health services 
 
Step 5 
 
Completed additional aspects of the guidebook including: 
• cover page 
• dedication 
• introduction 
• references 
 
Overview of Part Three 
 The outcome of this project is a guidebook on destigmatizing harm reduction that is 
based on a literature review on public perceptions of harm reduction and PWUD. The goals of  
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the guidebook are to decrease stigma in health care settings, and increase job satisfaction among 
health care professionals. A summary of the research findings that identify stigmatizing  
perceptions of harm reduction and PWUD, as well as recommendations for decreasing this 
stigma, have been written into a set of guidelines for destigmatizing harm reduction work. The 
guidebook is relevant for people who work in the field of addiction and substance use, as well as 
members of the general public. Organizations and individuals may distribute the guidebook as a 
tool for challenging commonly held stigmatizing perceptions of harm reduction and PWUD. The 
overall purpose of the project is to better support harm reduction service provision and evidence 
based drug policy, a critical need as Canada responds to the current opioid crisis. 
 
 
Figure 2: Example of Excel Spreadsheets used in Step 3 
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• @'374&!3*(,+&-+-!345&'3+*(+!;3'%!(83+*'-?!&*.!.+(,+&-+-!+45&'%/!&*.!)1+,&88!<0&83'/!)6!(&,+>!!
• A+(&0-+!-)(3+'/!%&-!8+73'343B+.!-'374&!');&,.-!5+)58+!;%)!0-+!.,07-?!3'!3-!345),'&*'!')!+C&43*+!%);!'%3-!4&/!345&('!/)0,!;),D!;3'%!'%3-!7,)05>!!E+68+('31+!<0+-'3)*-F!!
• :);!;+,+!/)0!'&07%'!')!5+,(+31+!5+)58+!;%)!0-+!.,07-9!
• :);!.)!/)0!5+,(+31+!5+)58+!;%)!0-+!.,07-!').&/9!
• $%+*!.)!/)0!*)'3(+!6++83*7-!)6!6,0-',&'3)*?!,+-+*'4+*'?!),!&1)3.&*(+!');&,.-!(83+*'-9!
• $%+*!%&1+!/)0!6+8'!4),+?!),!8+--?!3*(83*+.!')!;),D!;3'%!(+,'&3*!5+)58+!),!7,)05-9!
• :);!.)!/)0!(%+(D!3*!;3'%!/)0,!23&-+-!&*.!+'%3(&8!-'&*.&,.-9!!!!!!!!!!!
! ! !
!
""!!!!
!"##$%%&"'()*+,(+$-"#./01(-0$%(10.(
+$2"/+$()$*'/13(*--/#./014(
(!!
Key Issue:  
 !

Background 
information: !!!
!!!!!!!! !

! ! !
!
"#!!!!!
!
"#$%&'%!(&)!*%+',!-$).!)#/*01+&'!+'02*/#3!
!
• $%&'%()*+,!+%,(-*.%!*/0(&-)!12!3'4,)!4)%!1+!-5%/)%6.%)!(+3!1-5%')!
! 7'%.%+-*1+!1'!/(+(,%/%+-!12!*+2%&-*14)!3*)%()%!
! 8%34&*+,!'*)9!:%5(.*14')!)4&5!()!4)*+,!4+)-%'*6%!%;4*0/%+-!(+3!+1!)40%'.*)*1+!
! <4:)-*-4-*+,!5*,5!'*)9!3'4,)!)4&5!()!5%'1*+!=*-5!/1'%!/(+(,%(:6%!3'4,)!6*9%!/%-5(31+%!1'!:40'%+1'05*+%!
! <1&*(6!)4001'-!2'1/!)-(22!(+3!0%%')!
! >%+-(6!5%(6-5!(+3!)1&*(6!)%'.*&%!(.(*6(:*6*-?!
! @1//4+*-?!(+3!&1/21'-!!!!!!"A!!!!!!
Case examples:   
!!!!!!!! !
!

! ! !
!
"#!!
 

?    $%1)!9&&</'5.!+,-&!*:!9,0!@,*!2%&'!2,0=/'5!2/)%!+</&').!2%,!.&&-!.)*+=!/'!)%&/0!:1))&0'.C !B1;&!@,*!&;&0!9&<)!)%1)!.,-&,'&!+,*<3!',)!?&!%&<:&3C!!D.!)%&0&!1',)%&0!21@!,9!.&&/'5!)%&!./)*1)/,'!)%1)!1<<,2.!9,0!-,0&!%,:&C!!!!
Take-away 
message:!
!
!
• E%&!5,1<!,9!0&3*+/'5!%10-!3&+0&1.&.!.)0&..!1'3!?*0',*)!9,0!+10&!:0,;/3&0.>!!F!!
• (%/9)/'5!)%&!9,+*.!,9!@,*0!2,0=!90,-!9/G/'56!%&1</'5!,0!0&.,<;/'56!),!:0,;/3/'5!,:)/,'.!1'3!0&3*+/'5!%10-6!+1'!0&</&;&!:0&..*0&!,'!@,*!1'3!@,*0!+</&').>!!#H!!!!!!
• I'3&0!1!%10-!0&3*+)/,'!:%/<,.,:%@6!1'@!.&0;/+&!)%1)!/'+<*3&.!.*::,0)!1'3!,:)/,'.!9,0!0&3*+/'5!0/.=!1'3J,0!&'%1'+/'5!A*1</)@!,9!</9&!+1'!?&!+,'./3&0&3!.*++&..9*<>!!
• K01+)/+/'5!2/)%!1!%10-!0&3*+)/,'!-1'31)&!-1@!/'+0&1.&!)0*.)6!/-:0,;&!0&<1)/,'.%/:.!1'3!&'%1'+&!4,?!.1)/.91+)/,'>!!"L!!
• (&&!)%&!)1?<&!,'!:15&!"F!!9,0!1'!,;&0;/&2!,9!MB10-!N&3*+)/,'!K0/'+/:<&.!9,0!B&1<)%+10&!(&))/'5.O!1.!:0&.&')&3!/'!)%&!0&.&10+%!,9!B12=!&)!1<>!PQ"L>!!R!!!!!!!!!
! ! !
!
"#!!
Harm Reduction Principles for Healthcare Settings 
 
Hawk et al. 2017   $ 
 
Principle 
 
Definition 
 
Approaches 
Humanism Clients are seen as human 
beings. 
Care providers seek to 
understand the human need 
driving their behaviours. 
Acceptance of clients’ choices. 
Approachable for clients’ needs. 
Withholding judgments and 
grudges. 
Pragmatism Clients are held to realistic 
standards of health.  
Care providers account for 
the way that societal norms 
contribute to client health. 
Abstinence or decreasing drug 
use should not be prioritized or 
assumed to be the ultimate goal. 
Decisions are based on level of 
harm to clients rather than moral 
or societal standards. 
Individualism Everyone has unique needs, 
strengths, and experiences. 
Interventions offered reflect 
client diversity and 
individuality. 
Care providers offer flexible 
interventions appropriate to 
individuals’ needs and 
experiences. 
Not relying on universal 
protocols. 
Autonomy Respect for individuals’ rights 
to make their own choices. 
Professionals offer options, 
education and suggestions while 
respecting client input and 
decisions. 
Incrementalism Appreciation of each small 
effort.  
Acknowledgement that 
change takes time and 
includes set-backs. 
Highlight all positive client effort 
and strengths. 
Set realistic goals. 
Reassure that setbacks are a 
normal part of moving forward. 
Accountability 
without 
termination 
Holding people responsible for 
the consequences of their 
behaviour without shaming, 
punishing or trying to change 
their minds. 
Help clients understand the 
impacts of their choices. 
Do not penalize choices you 
disapprove of. !!!
! ! !
!
"#!
!
!
"#!$%&'&$()!*+!,*$&()!$*-'#.',!'/('!*00*,#!
1*(),!+*%!0*,&'&2#!$/(-1#3!
!
Key Issue:  !
 
This guideline encourages health professionals to redirect critical 
beliefs about their clients towards critical thought about the social 
oppressions that limit clients, and critical thought on their own 
professional role in that process.!!!
!"#$%&$'()*+,-.&/#001&12-$+&-/&12,/+,.3&+2'&*-.+'4+&/$-%&-.'&-/&5'$1-.#0&$'15-.1,6,0,+7&
+-&1-*,#0&$'15-.1,6,0,+7&/-$&$'()*,.3&,.'8),+,'19&:;<&5=>?>@!!
!
Background 
information: !!!
!!!!!!!! !

! 4&,$%&5&-('&*-6!,'&15(!(-7!5(%1&-()&8('&*-!
! 9*2#%':!
! ;-,'(<)#!*%!)*=!>?()&':!/*?,&-1!*0'&*-,!
! 9/:,&$()!(-7!5#-'()!/#()'/!$/())#-1#,!
! @#2#%#!'%(?5(!
! A($B!*+!,*$&()!#-1(1#5#-'!(-7!,?00*%'!
! A($B!*+!#7?$('&*-!*00*%'?-&'&#,!
! 4#$%#(,#7!#50)*:5#-'!*00*%'?-&'&#,!!!!
 
 
! ! !
!
"#!
 
 
3 Types of Stigma and Oppressive Outcomes 
 
Corrigan & Wassel’s research outlines different ways that social stigma can counter 
health and wellness goals of people who use drugs. 20 
Type of 
Stigma 
 
Definition 
 
Oppressive Outcome 
Public stigma Negative stereotypes and 
judgments from society 
Social rejection 
Mistreatment & discrimination 
Limited access to housing, 
employment, social services, 
insurance and treatment 
Self Stigma Internalization of negative 
stereotypes and 
judgments from society 
Low self-esteem 
Low self-efficacy 
Defeated outlook 
Decreased motivation 
Psychological distress 
Label Stigma Prejudice and 
discrimination associated 
with labels such as 
diagnoses or derogatory 
terms. 
 
Incentive to avoid treatment or 
social situations that confirm or 
draw attention to a label 
Isolation 
Private suffering 
Diminished relationships  !!!!!!!
! ! !
!
"#!!!
Case examples:   
!!!!!!!! !
!


?   F%!=2+0!=+,/!1.(20!/41'4%'!.%!,4)&!&4*'!54%0&.;)0'!04!02'!/,/0'1.5!/0.(1+!'A8'&.'%5'3!;,!8'48*'!,4)!=4&@!=.02G!!>2'%!1+@.%(!5+&'!8*+%/!4&!/'00.%(!(4+*/<!24=!34!,4)!+5@%4=*'3('!;+&&.'&/!+!5*.'%0!1+,!6+5'G!!
 
 
 
! ! !
!
"#!
 
 
Take-away 
message:!
!
!
• $%&'(%!)*+,!-./-+012%!.-%!3*-&43%4-!4%2%*5%3!%1&.6,!7.368%1+9!4%'4&02,!013!/(08%!:4&8!+,%8-%(5%-!013!-&2*%+;!0+!(046%<!!
• =:!;&.!:%%(!24*+*20(!&:!;&.4!2(*%1+-9!/%!24*+*20(!&:!+,%*4!-.44&.13*16!-&2*0(!-;-+%8-!+,0+!80;!/%!&/5*&.-(;!&4!-./+(;!3*-%8'&)%4*16!+,%8!:4&8!'&-*+*5%!2,016%<!!
• >,%1!'4&8&+*16!2(*%1+!0.+&1&8;!013!%8'&)%48%1+9!*+!*-!*8'&4+01+!+&?!!
!!4%0(*-+*20((;!2&1-*3%4!(*:%!2*42.8-+012%-!013!*1%@.0(*+*%-!+,0+!(*8*+!2(*%1+!&'+*&1-!!!
!!4%2&61*A%!2(*%1+-B!4%-*(*%12%!013!2&88%13!+,%*4!'04+*2*'0+*&1!*1!,048!4%3.2+*&1!!!!!!!!3%-'*+%!+,%!2,0((%16%-!+,%;!80;!/%!(*5*16!)*+,!!
• !"#$%&'())
!!!C)04%1%--!&:!-&2*0(!2&1+%D+!3&%-!1&+!8%01!0--.8*16!+,0+!0((!'%&'(%!),&!.-%!!!!!!!!34.6-!04%!&''4%--%3<!E&4!-&8%9!34.6!.-%!*+!*-!0!2,&*2%!013!0!(*:%-+;(%!+,%;!04%!!!!!!!!022.-+&8%3!+&<!
!!>,%1!'402+*2*16!0)04%1%--!&:!-&2*0(!-;-+%8-9!2&15%;!*+,-+./0)12/)-3/49!:&4!+,%!!!!!!!!)0;!'%&'(%!105*60+%!+,%*4!2*42.8-+012%-<!!!
 !
)
)
)
)
)
)
)
)
! ! !
!
"#!
!
"#$%&'#(%&!)%*+,+-&./01+&'!!
*020*+#34!0&)!05-+)!2%$,60,+-&7!
 
 
Key Issue:  
 !
!$%&'!()&*+,&-+!.//+0'!1,&+-231+-2+0+*!*&0+12&.-'!/.0!4.05&-(!2%0.)(%!2+-'&.-'!2%62!16-!60&'+!4%+-!1,&+-2!(.6,'!*&//+0!/0.7!(.6,'!./!%+6,2%!80./+''&.-6,'9!!!
 
Background 
information: !!!
!!!!!!!! !
!:2)*&+'!'%.4!2%62!4%+-!%+6,2%!80./+''&.-6,'!&-2+-2&.-6,,;!.0!)-&-2+-2&.-6,,;!&78.'+!2%+&0!(.6,'<!=6,)+'<!6-*!>+,&+/'!.-!1,&+-2'<!&2!%6'!6!*&'+78.4+0&-(!&78612!2%62!)-*+07&-+'!1,&+-2!(.6,'<!6-*!,&7&2'!1.,,6>.062&.-!6-*!1..8+062&.-!&-!%+6,2%!'+0=&1+!'+22&-('9!!?<@"!!
8*#+-&,!#(0#!0$%!2%$,60,+5%4!*-%$*+5%!-$!+/2-,+&'!-&!*9+%&#,!+&*96)%:!
• A'')7&-(!1,&+-2'B!),2&762+!(.6,'!&-=.,=+!*+10+6'&-(!.0!1+6'&-(!*0)(!)'+!
• $0;&-(!2.!1.-=&-1+!1,&+-2'!2%+;!'%.),*!*+10+6'+!.0!1+6'+!*0)(!)'+!
• C78,;&-(!8+.8,+!60+!,+''!*+'+0=&-(!./!160+!>+16)'+!2%+;!10+62+!2%+&0!.4-!80.>,+7'!
• D.-=+;&-(!7.06,!.0!=6,)+3*0&=+-!E)*(+7+-2!!F%+-!&2!688+60'!2%62!1,&+-2'!%6=+!*&//+0&-(!(.6,'!2%6-!%+6,2%!80./+''&.-6,'<!&2!16-!>0&-(!)8!1.77.-!'2+0+.2;8+'!6>.)2!8+.8,+!4%.!)'+!*0)('!2%62!1%60612+0&G+!2%+7!6'!)-1..8+062&=+<!8..0,;!7.2&=62+*!6-*!-.2!265&-(!0+'8.-'&>,;!/.0!2%+&0!%+6,2%9!!$.!*+10+6'+!'2&(76!6-*!/0)'2062&.-!2.460*'!1,&+-2'<!'.7+!%+6,2%!80./+''&.-6,'!612&=+,;!615-.4,+*(+!2%62!)-5-.4-!8+0'.-6,!+H8+0&+-1+'<!6-*!';782.7'!./!6**&12&.-<!16-!,&7&2I!
• 0+6,&'2&1!.82&.-'!
• *+1&'&.-3765&-(!16861&2;!!
• '+,/34.02%!!
• '+,/320)'2!!!F%+-!%+6,2%!80./+''&.-6,'!*&'6(0++!4&2%!1,&+-2'B!*+1&'&.-'<!')1%!6'!*&'1.-2&-)&-(!6-2&=&06,!7+*&162&.-<!>&-(&-(!6/2+0!*+2.H<!.0!7&''&-(!6-!688.&-27+-2<!062%+0!2%6-!,6>+,,&-(!1,&+-2'!6'!-.-1.78,&6-2<!0+15,+''!.0!8..0,;!7.2&=62+*<!2%+;!16-!0+76&-!1,&+-231+-20+*!6-*!/.1)'!.-!'20+-(2%+-&-(!1,&+-2'B!16861&2;!2.!765+!*+1&'&.-'!6>.)2!2%+&0!%+6,2%9!!!!!!!!!!!!?<"J!!!!!!!
 
 
! ! !
!
"#!
Case examples:   
!!!!!!!! !
!$%&'(!)*!%!(+&*'!)(!%!,&)-%&.!/%&'!*'00)(1!02%0!345546*!%!2%&-!&'7+/0)4(!,2)54*4,2.!43!/%&'8!$%&'(!9%5+'*!02'!*'&9)/'*!*2'!,&49)7'*:!;+0!%0!0)-'*!&+(*!)(04!*)0+%0)4(*!02%0!/2%55'(1'!2'&!2%&-!&'7+/0)4(!,&)(/),5'*8!!!

" $%&'(!7'/)7'7!02%0!02'!;'*0!6%.!04!&'7+/'!2%&-!)(!02)*!/%*'!6%*!04!*+,,4&0!02'!-402'&A*!2%&-!&'7+/0)4(!'334&0*!%(7!,&'*'&9'!2'&!0&+*0!)(!2'%502!*'&9)/'*8!!$%&'(!=('6!3&4-!'E,'&)'(/'!02%0!&'*,'/03+5!&'5%0)4(*2),*!6)02!/5)'(0*!;'00'&!*+,,4&0!02')&!2'%502:!*'53I64&02:!%(7!/2%(/'*!43!/4(0)(+)(1!04!+*'!*'&9)/'*!02%0!,&4-40'!,4*)0)9'!/2%(1'*!)(!02')&!;'2%9)4+&8!!!
?     <2%0A*!)0!5)='!34&!.4+!62'(!.4+!*''!/5)'(0*!&','%0'75.!+*)(1!*'&9)/'*!6)024+0!-%=)(1!,4*)0)9'!/2%(1'*!.4+A7!5)='!04!*''!)(!02')&!5)9'*J !<2'(!.4+!7)*%,,&49'!43!%!/5)'(0A*!;'2%9)4+&:!246!74!.4+!*0&)9'!04!='',!.4+&!)(0'&%/0)4(*!'-,46'&)(1!04!02'-J!!
 
Take-away 
message:!
!
!
!"#$%&'(#)*#('+,,%-#(*+#%&%./(*&0('#-1&2#)1&((
01"$'$%&3.*4$&2("*,*"$#/(5(
(
• K&49)7'!4,0)4(*!
• K&4-40'!/455%;4&%0)4(!&%02'&!02%(!/44,'&%0)4(!
• D%5%(/)(1!'(/4+&%1'-'(0!6)02!/5)'(0*A!&)120!04!*%.!L(4A!
• M/=(465'71'!4;*0%/5'*!%(7!2'5,!&'7+/'!02'-!62'(!,4**);5'!!
• K&4-40'!*'53I64&02!%(7!*'53I'*0''-!
• N4(*)7'&!%55!34&-*!43!2%&-!&'7+/0)4(!%(7!*.-,04-!-%(%1'-'(0!04!;'!64&0262)5'!14%5*!%(7!,&47+/0)9'!64&=!
6*+#$%&5!!
! O2)*!1+)7'5)('!)*!(40!*%.)(1!02%0!.4+!/%(A0!;'!*)(/'&'!6)02!.4+&!/5)'(0*!%(7!5'0!02'-!=(46!62'(!.4+!7)*%1&''!6)02!02'-8!G0A*!*%.)(1!02%0!.4+&!14%5!)*!(40!04!/4(9)(/'!02'-!04!74!62%0!.4+!6%(0:!;+0!04!,&49)7'!02'-!6)02!02'!;'*0!,4**);5'!*+,,4&0!)(!-%=)(1!02')&!46(!)(34&-'7!7'/)*)4(*8!
! G(!/%*'*!62'(!/4(7)0)4(*!%&'!5)3'I02&'%0'()(1:!)0A*!4=!04!0'55!/5)'(0*!02%0!02'.!-+*0!%/0!4&!02')&!5)9'*!/4+57!;'!%0!&)*=8!!
! ! !
!
"#!!
!
"#$$%&'!()*)&+,!,-.)!(%+,/0!+/!1),,!+/!
2+*+(-*(!&-/3!4)5+6-%#&/7!
!
!
Key Issue:  
 !
!$%&'(%!)*%!+&*%!,-).!,-%/*!)00/1,/&.2!3-%.!,-%!4&156!&4!-%)(,-!6%*7/1%!/6!*%051/.8!*/69!:%-)7/&5*6!;/,-&5,!)19.&;(%08/.8!8%.%*)(!;%((.%66<!/,!1).!4%%(!0/6+/66/7%!,&!1(/%.,6<!).0!/,!+/66%6!&''&*,5./,/%6!4&*!65''&*,/.8!&7%*)((!=5)(/,>!&4!(/4%!,-),!65**&5.06!,-%!65:6,).1%!56%!/665%62!!
!
!
Background 
information: !!!
!!!!!!!! !
!$)*,/1/').,6!&4!-)*+!*%051,/&.!'*&8*)+6!*%'&*,!,-),!;-%.!-)*+!*%051,/&.!8&)(6!4&156!&.(>!&.!'*&'%*!0/6'&6)(!&4!.%%0(%6!).0!*%051/.8!,*).6+/66/&.!&4!0/6%)6%<!/,!4%%(6!)6!,-&58-!,-%!6%*7/1%6!)*%!+&*%!4&*!'5:(/1!/.,%*%6,6!,-%.!,-%!.%%06!&4!')*,/1/').,62!!#?!!$)*,/1/').,6!%@'*%66%0!-)7/.8!*%)6&.6!4&*!1-&&6/.8!-)*+!*%051,/&.!'*)1,/1%6!:%>&.0!,-%!+)/.6,*%)+!4&156!&.!'5:(/1!6)4%,>!/665%62!!#A<#?!!B-%/*!*%)6&.6!/.1(50%C!
• D)/.,)/./.8!6&1/)(!*%(),/&.6-/'6!
• E11%66!,&!+%.,)(!-%)(,-!).0!6&1/)(!6%*7/1%6!
• $5*65/,!&4!8%.%*)(!(/4%!8&)(6!651-!)6C!
! F,):(%!-&56/.8!
! F,%)0>!/.1&+%!
! G%7%(&'+%.,!6%(4H%6,%%+!).0!6%(4H%44/1)1>!!!!$%&'(%!;-&!56%!0*586!&5,(/.%0!6&+%!)1,/7/,/%6!,-),!/.1*%)6%0!,-%/*!6%(4H%6,%%+!).0!6%(4H%44/1)1>C!
• I%1&..%1,/.8!;/,-!4)+/(>!
• I%1%/7/.8!'*&7/.1/)(!6&1/)(!&*!0/6):/(/,>!65''&*,!
• J/.0/.8!%+'(&>+%.,!
• K051),/&.!&*!L&:!69/((!&''&*,5./,/%6!
• M+'*&7/.8!,-%/*!)''%)*).1%!
• N&++5./,>!6%*7/1%!&''&*,5./,/%6!
• F%%/.8!,-%!7)(5%!&4!,-%/*!(/7%0!%@'%*/%.1%6!!!#A<#?!!!!!
! ! !
!
""!!!
Case examples:   
!!!!!!!! !
!

" A+!;8)$(B!%'$1!.5@*/-$4*!&'(!-.!%'1'3*!#$%B(!)$(>!5*8'4$.0)(!)'-8*)!-8'1!(**>!-.!01,*)(-'1,!#$%B(!<*)(<*/-$4*!.+!8$(!1**,(6!'-!&.)(*6!#$%!%'2!1*4*)!8'4*!'3)**,!-.!'12!(*)4$/*(!,0*!-.!+**7$13!/.*)/*,!$1-.!(.%*-8$13!-8'-!,.*(!1.-!(*)4*!8$(!$1-*)*(-(9!C-!5*(-6!#$%!%'2!8'4*!'3)**,!-.!*13'3*!$1!5'($/!8')%!)*,0/-$.1!(-)'-*3$*(6!50-!'!%'@.)!)$(>!-.!8$(!8*'7-8!'1,!('+*-26!*4$/-$.1!+).%!8$(!8.%*6!%'2!8'4*!5**1!%$((*,9!!
?    D8'-!/7$*1-!1**,(!')*!$%<.)-'1-!+.)!2.0!-.!>1.&!'5.0-!$1!2.0)!&.)>E !:.&!,.!2.0!(**>!.<<.)-01$-$*(!-.!5*--*)!01,*)(-'1,!&8'-B(!$%<.)-'1-!-.!'!/7$*1-!5*($,*(!2.0)!/.%%.1!8')%!)*,0/-$.1!3.'7(E!!!!!
Take-away 
message:!
!
!
• F0(-'$1$13!8')%!)*,0/-$.1!'1,!8*'7-8!3.'7(!$(!/8'77*13$13!'1,!01)*'7$(-$/!&8*1!5'($/!1**,(!7$>*!(0<<.)-!+).%!7.4*,!.1*(!'1,!(*/0)*!8.0($13!')*!1.-!%*-9!!
• D8*1!<.(($57*6!<).4$,*!(*)4$/*!.<-$.1(!-8'-!',,)*((!8.0($136!+$1'1/$'76!(./$'7!'1,!5'($/!1**,(!.+!/7$*1-(9!!
• D8*1!<.(($57*6!(8.&!$1-*)*(-!$1!/7$*1-(B!7$4*(!.0-($,*!.+!-8*$)!(*)4$/*!1**,(9!C(>!-8*%!&8'-B(!$%<.)-'1-!-.!-8*%9!!
• ;)*'-*!'1,!(0(-'$1!(0<<.)-$4*!*14$).1%*1-(!-8'-!/.14*2!$1-*)*(-!$1!(*)4$13!-8*!1**,(!.+!/7$*1-(6!1.-!@0(-!$1-*)*(-!$1!0<8.7,$13!<.7$/2!%'1,'-*(9!!!!!
!
! ! !
!
"#!
!
"#$%!$&'()*+,-!+.!-,*!.(//,$*+-0!
.(1.*#-)&!(.&2!+*!.(//,$*.!/&,/3&!#-'!
),%%(-+*+&.4!
!
Key Issue:  
 !
!$!%&''&(!')*+,-%,+.)&(!./0.!1,%-,0*,*!+234)%!*2++&-.!5&-!/0-'!-,12%.)&(!)*!./0.!).6*!%&(1&()(7!)44)%).!1-27!2*,!0(1!./0.!).!8)44!)(%-,0*,!+-&34,'*!0**&%)0.,1!8)./!1-27*9!""!!
!
!
Background 
information: !!!
!!!!!!!! !
!
5*('+&.!.6,7!*6#*!6#$%!$&'()*+,-!6#.!-,*!1&&-!8,(-'!*,9!!
! :(%-,0*,!1-27!2*,!&-!-,40+*,!-0.,*!
! :(%-,0*,!1-27!.-055)%;)(7!0(1!%-)',!
! :(%-,0*,!./,!(2'3,-!&5!+,&+4,!8/&!2*,!1-27*!)(!*2--&2(1)(7!%&''2().),*!
! <,%-,0*,!'&.)=0.)&(!.&!,(707,!)(!.-,0.',(.!&-!.&!-,12%,!*23*.0(%,!2*,!!!!!!"#>"?>"@!!
:-!),-*$#.*2!$&.&#$)6!.6,7.!*6#*!&-8,$)&%&-*!'$(0!),-*$,3!%,'&3.A!!
! $-,!(&.!,=0420.,1!&-!30*,1!&(!,=)1,(%,!&5!,55,%.)=,(,**!!
! <&!(&.!1,%-,0*,!&-!1,.,-!1-27!2*,!!
! :(%-,0*,!=)&4,(%,!0(1!=&40.)4).B!)(!./,!)44)%).!1-27!'0-;,.!!
! <)*+-&+&-.)&(0.,4B!.0-7,.!0(1!+2()*/!%,-.0)(!1,'&7-0+/)%*!
! C&(54)%.!8)./!/2'0(!-)7/.*!!!!!!"D>"E>"F>"G>#H>#I!!!
;&-&8+*.!,8!6#$%!$&'()*+,-!.&$<+)&.9!
 
=&)$&#.&'!'+.&#.&!$#*&.!JK:L>!KCL>!MNO!!"D>"E>#"P#D!$!',.0P0(04B*)*!1,'&(*.-0.,*!./0.!&+)&)1!07&()*.!./,-0+),*!0(1!(,,14,!*B-)(7,!+-&7-0'*!-,12%,!K:L!.-0(*')**)&(!0'&(7!+,&+4,!8/&!2*,!)(Q,%.)&(!1-27*!3B!@HR!9!!!##!
!
=&)$&#.&'!$+.>.!#..,)+#*&'!7+*6!'$(0!(.&!.()6!#.A!
• SB-)(7,!*/0-)(7!
• SB-)(7,!-,2*,!
• T234)%!)(Q,%.)(7!
• <)*%0-1,1!(,,14,*!)(!+234)%!*+0%,*!!!!"#>#@>#E>#F!!!
! ! !
!
"#!
!
"#$%#&'#(!)*#%()'#'!&+(!)*#%()'#!,)%-&./-/#'!
• $%&'()*&!(&+,-*!(')..&(!/01!+2,&'!,-&!).&3435!)2!+!*+2&!436&7,4)3!2+7484,9:!!/;!
• <!=&,+>+3+89*4*!*-)?*!3)!(&+,-!@9!)%&'()*&!-+*!)77A''&(!43*4(&!)2!+!*+2&!436&7,4)3!2+7484,9:!!"/!
!
"#$%#&'#!/+!(%012%#.&-#(!$%/,#!
• B4534247+3,89!8)?&'!'+,&*!)2!('A5>'&8+,&(!7'4=&!?+*!2)A3(!+=)35!.&).8&!?4,-!*A@*,+37&!A*&!(4*)'(&'*!?-)!,))C!.+',!43!-+'=!'&(A7,4)3!.')5'+=*!+3(!,'+43435:!#D!
• $.4)4(!+5)34*,!,'&+,=&3,*!+'&!&22&7,4%&!+,!'&(A7435!.+',474.+,4)3!43!,-&!488474,!('A5!=+'C&,:!!/E!
!
3+$%#&'#!/+!4#)4.#!'##5/+1!-%#&-,#+-!!<=)35!.&).8&!?-)!A*&(!+!*+2&!436&7,4)3!2+7484,9F!
• !GH1!!*,+',&(!+!(&,)I!.')5'+=!!#G!
• 0J1!*,+',&(!+((47,4)3!,'&+,=&3,K!+3(!"/1!*,)..&(!A*435!436&7,4)3!('A5*!!#"!
!
3,4%)*#(!60&./-7!)8!./8#!8)%!4#)4.#!9/-:!'0;'-&+$#!0'#!(/')%(#%'!!!<((4,4)3+8!@&3&24,*!2)'!.&).8&!?-)!A*&!-+'=!'&(A7,4)3!.')5'+=*!!4378A(&!437'&+*&(!)..)',A34,4&*!2)'!*)74+8!7)33&7,4)3!+3(!*A..)',K!2&&8435*!)2!@&8)35435K!+3(!!4=.')%&(!+,,4,A(&*!,)?+'(!,-&4'!+((47,4)3K!+88!)2!?-47-!7)3,'4@A,&!,)!@&,,&'!,'&+,=&3,!)A,7)=&*!+3(!)%&'+88!LA+84,9!)2!842&:!!GJKGHK#/!!
<)-#=!M,!4*!4=.)',+3,!,)!3),&!,-+,!*)=&!-+'=!'&(A7,4)3!.')5'+=*!4378A(&!(').>43!7&3,&'*K!+77&**!,)!7)A3*&88435!+3(!*)74+8!*&'%47&*K!+3(!-),!=&+8*:!N-&*&!+((4,4)3+8!*&'%47&*!'&*)8%&!*)=&!@+*47!3&&(*!)2!.&).8&!?4,-!*A@*,+37&!A*&!(4*)'(&'*!+3(!84C&89!7)3,'4@A,&!,)!,-&!.)*4,4%&!)A,7)=&*!)A,843&(!+@)%&!*A7-!+*!'&(A7,4)3*!43!('A5!A*&!+3(!('A5>'&8+,&(!7'4=&:!!#D!
!
!
!
Case examples:   
!!!!!!!! !
!
! <!5))(!&I+=.8&!)2!=4*.&'7&.,4)3*!+3(!=4*'&.'&*&3,+,4)3*!)2!-+'=!'&(A7,4)3!4*!*-)?3!43!,-4*!3&?*!-&+(843&!@&8)?!'&5+'(435!).4)4(!+5)34*,!,'&+,=&3,:!!
!!!
 
 
 
 
! ! !
!
"#!!$%&'!()*)'+,-(&.!/,((&'0*!1)2&!0%&*&!3,!4'/%511&'3&.6!)0!+&&.*!'&350)7&!8-,8535'.5!59,40!*49*05'/&!4*&!0%50!0%&!(&.)5!5'.!3,7&-'(&'0!%57&!%)*0,-)/511:!*488,-0&.;!!<0)3(5!5'.!()*)'+,-(50),'!59,40!.-43!4*&!.&/-&5*&*!8491)/!*488,-0!+,-!&7).&'/&=95*&.!.-43!8,1)/:!0%50!8&,81&!>)0%!*49*05'/&!4*&!8-,91&(*!'&&.;!!!

?    B5'!:,4!0%)'2!,+!/,((,'!()*8&-/&80),'*!59,40!:,4-!/1)&'0*!,-!:,4-!>,-2C !D,>!>,41.!:,4!1)2&!0,!5..-&**!0%&*&!()*8&-/&80),'*C!!
 
 
 
 
Take-away 
message:!
!
!
• D5-(!-&.4/0),'!)*!0%&!(,*0!&++&/0)7&!*0-50&3:!-&*&5-/%&.!0%4*!+5-!+,-!.&/-&5*)'3!8-,91&(*!5**,/)50&.!>)0%!.-43!4*&6!9,0%!+,-!8&,81&!>%,!4*&!.-43*6!5'.!0%&!9-,5.&-!/,((4')0:;!
!
• "#$%$&'!#(#)*&*%%!(+),%-!E&*&5-/%!*%,>*!0%50!5>5-&'&**!,+!0%&!9&'&+)0*!,+!%5-(!-&.4/0),'!)'/-&5*&*!8491)/!*488,-0!+,-!%5-(!-&.4/0),';!!FF6F#!!
• .*#/01!2#)*!3)+4*%%$+&#/%!2#&!5*!1$'1/6!$&4/7*&0$#/!)'!)(85/0)'3!8491)/!8&-/&80),'*;!FF!!?0!)*!)(8,-05'0!0%50!8&,81&!)'!0%&!+)&1.!4'.&-*05'.!>%50!%5-(!-&.4/0),'!)*6!5'.!/,--&/0!()*1&5.)'3!-&8-&*&'050),'*;!@&,81&!(5:!+)'.!:,4-!&A8&-)&'/&!(,-&!-&150591&!0%5'!-&*&5-/%!0%50!/,'0-5.)/0*!0%&)-!>,-1.7)&>*;!!!
!
!
!
! ! !
!
"#!
!"#$%#&'()*+,-%+.%-,*%"%/".*&%,0%*"1%
',22"#.%"-'%3&"2*3%.&#4+)&.5%
%
Key Issue:  
 !
!$!%&''&(!()*+,-.)!(&,-&(!+/&0,!1+2'!2)30%,-&(!-4!,1+,!-,54!46)(3-(*!,+7!3&88+24!+(3!1)+8,1!4)2.-%)!2)4&02%)4!&(!1)86-(*!%2-'-(+84!04)!320*49!!!
%
Background 
information: !!!
!!!!!!!! !

6"4+-7.%+-%3&"2*3%)"#&%!
• C:E!62).)(,-&(!4,2+,)*-)4!40%1!+4!())38)!4=2-(*)!62&*2+'4<!406)2.-4)3!-(F)%,-&(!;+%-8-,-)4!+(3!&6-&-3!+*&(-4,!,2)+,')(,4!+2)!8)44!%&4,8=!,1+(!C:E!,2)+,')(,9!
• G=!62).)(,-(*!HD#!C:E!-(;)%,-&(4!6)2!=)+2<!!E+(%&0.)254!406)2.-4)3!-(F)%,-&(!;+%-8-,=!+.)2,4!'&2)!,1+(!IJ<KKK<KKK!-(!8-;),-')!,2)+,')(,!4)2.-%)4!&;!C:ED2)8+,)3!')3-%+8!%&4,49!!L#<B#!!
6"4+-7.%+-%.,)+"2%8(.*+)&%"-'%&-0,#)&$&-*!
• C+2'!2)30%,-&(!4)2.-%)4!+2)!8)44!%&4,8=!,1+(!)(;&2%)')(,!+(3!-(%+2%)2+,-&(9!!
• M,03=!)4,-'+,)4!2)6&2,!,1+,!).)2=!IJ!60,!-(,&!&6-&-3!+*&(-4,!,2)+,')(,4!'+=!2)408,!-(!4+.-(*4!/),>))(!IBDIN!&(!%&4,4!&;!320*D2)8+,)3!%2-')<!%2-'-(+8!F04,-%)!4)2.-%)4<!+(3!,1);,9!!L#<B#!!!
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
! ! !
!
"#!
Case examples:   
!!!!!!!! !
!


?  F';!;'(.8!:'(!.1?,!/'!&,0)'28!/'!01/(-/1'20!.1?,!/+,!'2,!-3'<,G !
!
Take-away 
message:!
!
!!
• C+,!3,2,*1/0!'*!+-&9!&,8(4/1'2!12!)&,<,2/1'2!'*!12*,4/1'(0!810,-0,!/&,-/9,2/!4'0/0@!-28!0'41-.!D(0/14,!4'0/0@!-&,!2'/!-.;-:0!'3<1'(0!12!/+,!8-:H/'H8-:!;'&?5!!
• $0!-!+,-./+!)&'*,001'2-.@!:'(!-&,!12!-2!12*.(,2/1-.!)'01/1'2!/'I!
! )&,<,2/!/+,!0)&,-8!'*!91012*'&9-/1'2!/+-/!8191210+,0!)(3.14!0())'&/!*'&!:'(&!!!!!!!!!!!!!!!!;'&?!-28!:'(&!4.1,2/0!
! 0+-&,!:'(&!?2';.,8%,!'*!,<18,24,H3-0,8!+,-./+!0,&<14,0!!
!
! ! !
!
"#!
!
"#$$%&'(!'&#)'!*+,!*,-%.*./!*&0!-*1#0,!
*+,!23$*.'4#15!
!
!
Key Issue:  
 !
!$%&'!%&()*%!+,-.&//0-'()/!.&&)!1'2&,*(0'!*%(*!*%&0,!3-,4!0/!&..&2*05&6!*%0/!7108&)0'&!0/!(!,&90'8&,!*%(*!2)0&'*/!:&'&.0*!.,-9!*%&0,!7&'10'&!/1++-,*!('8!,&/+&2*;!!!
!
!
Background 
information: !!!
!!!!!!!! !

60)0*&.7!%+!"#$$%&'2-0!8+'0&*.'2%+)9!!C&,2&05&8!/-20()!/1++-,*!0/!(//-20(*&8!30*%!%07%&,!/&).B&/*&&96!:&**&,!/)&&+!('8!)-3&,!8&+,&//0-'!('8!('D0&*>;!!E1++-,*05&!1+)0.*0'7!0'*&,(2*0-'/!9(>!2-9:(*!*%&!8&*,09&'*()!09+(2*!-.!0'*&,'()0F&8!/*079(!('8!/%(9&!-'!9&'*()!%&()*%;!!GG!!!H&/&(,2%!-'!+-/0*05&!%&()*%!/&,502&!0'*&,(2*0-'/!08&'*0.0&8!2-99-'!2%(,(2*&,0/*02/!(9-'7!%&()*%!+,-.&//0-'()/!/12%!(/I!!
• C-/0*05&!50&3/!-'!*,&(*9&'*!0'*&,5&'*0-'/!('8!%(,9!,&812*0-'!+,(2*02&/!
• H&J&2*0-'!-.!9-,()!/*&,&-*>+&/!(:-1*!*%0/!+(*0&'*!8&9-7,(+%02!!!K!!! !
!
!
!
!
!
! ! !
!
"#!
!
"#$!%&#%'&!$(#!)*&!+,)-*!+&*.,/0&!%#*/1/2&!34+!4&-31/2&!/41&,3.1/#4*5!
!$%&'(')*!'+(*,-.('%+&!(/-(!&(%%0!%1(!(%!.2'*+(&!3*,*!0*&.,'4*0!-&!5**('+6!71+0-5*+(-2!/15-+!+**0&!&1./!-&!&-7*(89!+1(,'('%+9!/80,-('%+9!5*0'.'+*9!/86'*+*9!,*2-('%+&/':&9!,*.,*-('%+9!%..1:-('%+9!-+0!*5%('%+-2!&1::%,(;!!<=/*,*!3*,*!:*%:2*!3'(/!3/%5!>!.%120!&/-,*!'0*-&;?!!!@A!:;B!
!
C*6-(')*!'+(*,-.('%+&!(/-(!&(%%0!%1(!3*,*!0*&.,'4*0!-&!0*/15-+'D'+6E!)*,4-2!-+0!+%+F)*,4-2!5*&&-6*&!'5:28'+6!1+3%,(/'+*&&!%7!&*,)'.*&9!-+0!7**2'+6&!%7!4*'+6!(,*-(*0!2'G*!<6-,4-6*?!%,!<-!:'*.*!%7!&/'(?;!<=/%&*!3/%!3*,*!&(,**(!'+)%2)*0!0*&.,'4*0!3-+('+6!(%!4*!(,*-(*0!-&!-!,*-2!:*,&%+!3/*+!(/*8!-..*&&*0!/*-2(/!.-,*?!B!:;"HH!
!
Case examples:   
!!!!!!!! !
!
! I/*+!=%5!-::,%-./*0!-!(*-5!%7!%1(,*-./!/*-2(/!.-,*!:,%)'0*,&!'+!-!+*'6/4%,/%%0!G+%3+!7%,!/'6/!0,16!1&*9!/*!(%20!(/*5!/*!/-0!&85:(%5&!%7!:-'+!-+0!(/%16/(!/*!&/%120!6%!(%!(/*!/%&:'(-2;!=/*!-5412-+.*!0,')*,!&-'0!&-,.-&('.-228!<J%!8%1!,*-228!3-+(!(%!6%!(%!(/*!/%&:'(-2K?!'5:28'+6!(/-(!=%5!3-&!2'G*28!L1&(!-((*+('%+!&**G'+6!(%!%4(-'+!:-'+!5*0'.-('%+;!!

?    >+!3/-(!3-8&9!2-,6*!%,!&14(2*9!0%!8%1!0*5%+&(,-(*!(%!.2'*+(&!(/-(!(/*8!/-)*!3%,(/!(%!8%1K !
!
Take-away 
message:!
!
!
! R%1,!.2'*+(&!,*5*54*,!-+0!)-21*!8%1,!.%5:-&&'%+9!&1::%,(!-+0!-0)%.-.8;!!
! N1::%,(')*!'+(*,-.('%+&!:,%5%(*!4*((*,!5*+(-2!/*-2(/!7%,!8%1,!.2'*+(&;!!
! Q*2:'+6!.2'*+(&!.%++*.(!3'(/!-+0!1('2'D*!&%.'-2!&1::%,(!'+!(/*',!2')*&!.-+!.%54-(!'+(*,+-2'D*0!&('65-!-+0!&/-5*!(/-(!0-5-6*&!(/*',!/*-2(/!-+0!3*22F4*'+6;!!
! N1::%,(')*!'+(*,-.('%+&!,*L*.(!+*6-(')*!&(*,*%(8:*&!%7!:*%:2*!3/%!1&*!0,16&9!-+0!)-21*!/-,5!,*01.('%+!3%,G;!!
! ! !
!
"#!
 
!"#$%&"'$(%)$*'+$,%"-)%.$$#%./001'23%
%
Key Issue:  
 !
!$%&'!&()*+,-./!%/)!0(%1,0+%&(!2.&3!2-,0!4(.41(!20.!*5(!)&*65!-5!3/.2/!,.!7(!+0%11(/6-/6!./!4&.8(55-./%15!8.&!&(%5./5!-/+1*)-/6!7*&/.*,9!5(+./)%&:!,&%*'%!%/)!)-5+.*&%6('(/,;!!!<9<=!!
%
Background 
information: !!!
!!!!!!!! !
!>!'%?.&!4%&,!.8!0(%1,0!+%&(!4&.8(55-./%15@!2.&3!-/A.1A(5!(5,%71-50-/6!%/)!'%-/,%-/-/6!&(1%,-./50-45!.8!,&*5,!20-1(!+%&-/6!8.&!.,0(&5;!B,!-5!/.,!*/+.''./!8.&!,0(!('.,-./%1!,.11!.8!('4%,0-+!(/6%6('(/,!,.!6.!*//.,-+()!%'./6!+%&(!4&.A-)(&5;!!<C9D#!!
4150"..+1-%,"2+6/$!-5!,0(!('.,-./%1!+.5,!.8!4&.A-)-/6!+%&(9!+.'4%55-./!%/)!('4%,0:!,.!4(.41(!20.!0%A(!(E4(&-(/+()!,&%*'%;!!<C!!F0(/!+%&(!4&.A-)(&5!(E4(&-(/+(!+.'4%55-./!8%,-6*(9!,0(-&!G*%1-,:!.8!+1-(/,!+%&(!%/)!?.7!5%,-58%+,-./!)(+&(%5(;!!<C!!
4150"..+1-%,"2+6/$%"-)%,$$7+-6.%1,%*/'-1/2%5"8%'$./72%,'159%
%
• H&.I1./6()!.&!8&(G*(/,!(E4(&-(/+(5!.8!('4%,0-J-/6!2-,0!+1-(/,5!.&!,0(-&!8%'-1-(5!
• K(5-&(!,.!%75.&7!.&!%11(A-%,(!5*88(&-/6!.8!.,0(&5!
• L((1-/65!,0%,!,0(!)('%/)5!.8!,0(!?.7!+%//.,!7(!'(,!!!!!!!!<C!!
:1'#%$-;+'1-5$-2.%+50"&2%<1*%."2+.,"&2+1-%"-)%.2",,%51'"7%+-%2=$%,+$7)%1,%./*.2"-&$%
/.$%"-)%"))+&2+1-%3%!
! M&6%/-J%,-./%1!5*44.&,9!5*4(&A-5-./9!,&%-/-/6!%/)!,(%'!+.11%7.&%,-./!.44.&,*/-,-(5!+./,&-7*,(!,.!5-6/-8-+%/,1:!-/+&(%5()!?.7!5%,-58%+,-./!%/)!2-11-/6/(55!,.!2.&3!2-,0!4(.41(!(E4(&-(/+-/6!5*75,%/+(!*5(!4&.71('5;!!!!!!!!!!!!!
• N*44.&,-A(!2.&3!(/A-&./'(/,5!%/)!50%&()!,(%'!A%1*(5!-/+&(%5()!5(18I(5,(('9!4(&+(-A()!3/.21()6(!%/)!8((1-/65!.8!('4.2(&'(/,!%'./6!+%&(!4&.A-)(&5;!!!!!!!
• O(5(%&+0!5*66(5,5!,0%,!20(/!4&.8(55-./%15!8((1!2(11!5*44.&,()9!2(11!,&%-/()9!%/)!3/.21()6(%71(!.8!&(5.*&+(5!,0%,!5*44.&,!,0('5(1A(5!%/)!,0(-&!+1-(/,59!,0(-&!+1-(/,!+%&(!-'4&.A(59!%5!).(5!,0(-&!%7-1-,:!,.!('4.2(&!+1-(/,5;!!!!!!!!!!!!!!!!!!!"9<!!!
%
%
%
%
! ! !
!
"#!
!
Case examples:   
!!!!!!!! !
!


?   G-,!3+'!=-5!4&66!,%&'!=-5F.&!->&.,%&6<&2I!!@%0'/!-9!+66!4%&!-840-'1!=-5!%+>&!4-!+66&>0+4&!-.!<+'+)&!4%&1&!9&&60')1?!!
!
!
Take-away 
message:!
!
!
"#!$%&'!&()*+,-.#!/.&01!-,!-2!-'3.&,%#,!,$%,!3&.4(22-.#%52J!!
! A&&/!-54!+'2!54060:&!1588-.4!.&1-5.3&1!+4!,-./!+'2!0'!4%&0.!8&.1-'+6!60>&1?!
! K&!/0'2!4-!=-5.1&69!+'2!8.+3403&!1&6973+.&!4%+4!'-5.01%&1!=-5.!*-2=;!<0'2!+'2!180.04?!
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